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ABSTRACT 
 
Alzheimer’s disease is characterized by the formation of two major 
pathological hallmarks: amyloid plaques and neurofibrillary tangles. Although there 
have been many studies to understand the role of microglia in Alzheimer’s disease, 
it is not yet known how microglia can promote disease progression while actively 
phagocytosing amyloid plaques or phosphorylated tau (p-tau). Through stereotaxic 
injection of adeno-associated virus expressing mutant P301L tau (AAV-P301L-tau) 
into the medial entorhinal cortex (MEC) of both wild-type (WT) and APPNL-G-F mice, 
we demonstrate how amyloid plaques exacerbate p-tau propagation to the granule 
cell layer (GCL) of the hippocampus. However, in mice receiving the colony-
stimulating factor 1 receptor inhibitor (PLX5622), ~95% of microglia were depleted, 
which dramatically reduced p-tau propagation to the GCL. Although microglia 
depletion curtailed p-tau propagation, it also led to reduced plaque compaction and 
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an increase in overall amyloid-beta (Aβ) plaque presence. Additionally, we found 
microglia depletion resulted in greater p-tau aggregation in dystrophic neurites 
surrounding amyloid plaques. We investigated neurodegenerative microglia 
(MGnD), which are activated in response to amyloid plaques, for their propensity 
to release extracellular vesicles in comparison to homeostatic microglia. We 
discovered that MGnD, identified by Clec7a or Mac2 staining, strongly express 
Tumor susceptibility gene 101 (Tsg101), which is an ESCRT-1 protein and a 
marker for extracellular vesicles (EVs). To further investigate EV release and 
MGnD, a novel lentivirus expressing fluorescent      mEmerald conjugated to CD9 
(mE-CD9) was constructed and injected into the MEC of both WT and APPNL-G-F 
mice which allowed for visualization of mE-CD9+ puncta around individual 
microglia. CD9 is a tetraspanin and also a marker for EVs. We observed that the 
number of mEmerald+ particles surrounding MGnD was three-fold higher 
compared to non-diseased, homeostatic microglia. Sequential injection of mE-CD9 
and AAV-P301L-tau into the MEC revealed that microglia-derived EVs 
encapsulate pathologic p-tau, which is augmented by the MGnD phenotype. Taken 
together, these data provide strong evidence that MGnD exhibit increased 
secretion of tau-containing EVs, providing a possible mechanism for how amyloid 
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Chapter 1: Alzheimer’s disease and Neurodegeneration 
 
Chapter 1.1: Alzheimer’s disease  
 
 Alzheimer’s disease (AD) and other tauopathies are neurodegenerative 
diseases that develop generally with old age and lead to significant cognitive 
impairment and dementia. AD is the most common cause of dementia, presumed 
to be responsible for approximately 70% of all cases and afflicting a predicted 5.8 
million Americans in the year 2019 (Alzheimer's-Association 2020). Current 
projections suggest this number will balloon to 13.8 million within the next 30 years, 
constituting an estimated $1.1 trillion in healthcare costs. This growth in prevalence 
is due to the aged population of the USA growing along with a steadily-increasing 
average lifespan. AD is the sixth-leading cause of death in the United States. Once 
dementia has been diagnosed, death is expected generally within 7 years. The 
vast majority of AD cases, approximately 99%, do not show any obvious traces of 
genetic heritability (Lista, O’Bryant et al. 2015). Other tauopathies such as 
Frontotemporal dementia (FTD) or Chronic traumatic encephalopathy (CTE) 
among others exist, but occupy a much lower proportion of the causes of dementia. 
The clinical symptoms caused by Alzheimer’s disease do not become apparent 
until many years after the time Aβ first begins to accumulate (Masters, Bateman et 
al. 2015). Clinical symptoms of neurodegeneration include memory loss, 
behavioral changes, problems with language, depression, and loss of self-
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sufficiency among others. Symptoms present mildly in the early stages, but 
gradually becomes worse as the pathology and neurodegeneration progress over 
several years.  
Therapies 
Currently approved therapies designed to treat AD and other tauopathies 
do not halt or reverse any damage, but only aim to mitigate the cognitive symptoms 
of neurodegeneration. Four pharmacologic agents have thus far been approved 
for the treatment of AD and all are classified as central acetylcholinesterase 
inhibitors, with the exception of memantine, which is an NMDA receptor antagonist. 
The former class of drugs acts by inhibiting butyrylcholinesterase or 
acetylcholinesterase, or both, reducing the breakdown of acetylcholine and 
effectively making up for the deficit of functioning cholinergic neurons lost during 
the progression of the disease (Sharma 2019). The latter drug, memantine, is the 
last novel pharmacologic agent to receive approval for the treatment of AD by the 
FDA in 2003. Memantine modulates the excitability of neuronal circuits by blocking 
NMDA receptor channels, which can improve cognitive function (Johnson and 
Kotermanski 2006). A number of promising candidates are in the pipeline for 
potential approval in the treatment of AD or other neurodegenerative disease 
(Clayton, Van Enoo et al. 2017). These drugs vary widely in their 
pharmacodynamics and treatment strategy. These novel drugs vary widely in their 
pharmacodynamics and treatment strategy, but generally aim to reduce 
inflammation, address tau pathology, prophylactically prevent Aβ accumulation, 
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and improve cognitive ability. Without treatment options available to slow down, 
halt, or reverse disease progression, AD and other tauopathies will continue to 
remain fatal diagnoses. 
 Proteinopathy 
Neurodegenerative disorders such as AD are generally considered 
proteinopathies (Walker and LeVine 2000). Proteostasis becomes impaired with 
old age and is regarded as the cause of accumulation of toxic proteins such as 
amyloid-beta (Aβ) or misfolded tau that build up into large aggregates of senile 
plaques or neurofibrillary tangles (NFTs), respectively. Proteostasis can be 
considered a balance of many different aspects of protein generation, processing, 
and removal. These steps include translation, folding, post-translational 
modifications, oligomerization, as well as clearance through autosomes, 
enzymatic degradation, and lysosomal degradation (Vilchez, Saez et al. 2014, 
Kaushik and Cuervo 2015). Each of these steps is likely to influence the onset of 
proteinopathy and can become impaired with age.  
In AD and other tauopathies, the imbalance of proteostasis is particularly 
strong. For example, Aβ is generated by the abnormal processing of the amyloid 
precursor protein (APP) (O'Brien and Wong 2011) by beta-secretase as opposed 
to alpha-secretase. Beta-secretase is hypothesized to be overactive due to 
increased expression in the case of AD (Li, Lindholm et al. 2004, Zhao, Fu et al. 
2007). Additionally, the toxicity, propensity for aggregation, metabolism, and 
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function of the Aβ peptide is dependent on its length (Qiu, Liu et al. 2015). The 
ultimate length of the Aβ peptide is determined by subsequent stepwise cleavage 
by another enzyme, gamma-secretase, which takes place intracellularly. Age-
related impairments during this portion of the process could affect eventual plaque 
deposition. However, one study suggests that gamma-secretase cleavage of APP 
is not impaired due to normal aging (Dewachter, Van Dorpe et al. 2000). Although 
abnormal generation, processing, and clearance is hard to understand in sporadic 
cases of AD, we know that is involved in the pathogenesis of disease from 
examining the effects of familial AD gene mutations. These are all mutations that 
occur in either the APP gene itself, or in the subunits of the gamma-secretase 
protein. Studying the effects of disease-causing mutations in APP have revealed 
they frequently result in misfolded Aβ peptides which are more prone to 
aggregation, impaired cleavage by alpha or gamma secretases leading to longer 
peptides, or an overall increase in initial expression of the APP gene (Lichtenthaler 
1999, Sleegers, Brouwers et al. 2006, De Strooper 2007). Following intracellular 
gamma-secretase cleavage within endosomes, vesicular fusion with the cell 
membrane leads to the ultimate release of Aβ (Frykman, Hur et al. 2010). This Aβ 
is then free to aggregate into large neuritic plaques and initiate the amyloid 
cascade. 
There are many enzymes within the central nervous system (CNS) that are 
capable of cleaving extracellular Aβ to prevent aggregation (Miners, Barua et al. 
2011) and are generally metalloproteinases or serine and cysteine proteases. 
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Additionally, Aβ is transported out of the CNS from the interstitial fluid through the 
blood-brain-barrier (BBB). Interestingly, some mutations in APP have been 
investigated that purportedly slow this process (Monro, Mackic et al. 2002). In vitro 
studies have demonstrated the toxicity associated with both fibrillar forms and 
oligomeric forms of Aβ (Chafekar, Baas et al. 2008, Ajit, Udan et al. 2009). The 
plethora of amyloid-bearing mouse models developed for research often present 
with measurable cognitive decline in animals following substantial accumulation of 
plaques (Jawhar, Trawicka et al. 2012, Saito, Matsuba et al. 2014). Taken 
together, these findings provide the compelling rationale for developing therapeutic 
techniques to mitigate plaque burden and further illuminate the factors influencing 
their aggregation in our research. Given the myriad of possibilities affecting the 
development of senile plaques, pharmacologic agents are being developed to 
address many of the aforementioned components of the Aβ processing pathway.  
Tau Proteinopathy 
Tau is a microtubule-stabilizing protein that regulates microtubule assembly 
within neurons, but interacts with many other proteins (Trushina, Bakota et al. 
2019). Although Aβ plaques precede tau pathology for many years and causes 
significant cognitive impairment in mice, it is tau pathology that correlates most 
tightly with cognitive decline in patients (Nelson, Alafuzoff et al. 2012). In 
neurodegenerative diseases with tau pathology, tau is frequently abnormally 
hyperphosphorylated, which impairs its innate tubulin-binding function and also 
influences its intracellular localization (Lindwall and Cole 1984). Tau is expressed 
6 
by translation of the MAPT gene into 6 different possible isoforms through 
alternative splicing (Bakota, Ussif et al. 2017). Like with Aβ, tau processing can 
become dysregulated in AD, leading to the aggregation of tau species into 
oligomeric species, paired helical filaments (PHFs), and eventually NFTs. For 
example, the 4R version of tau is more prone to aggregation than other isoforms, 
and is thought to be involved in the development of AD and tauopathies (Schoch, 
DeVos et al. 2016, Barron, Gartlon et al. 2020). In Pick’s disease, familial 
mutations in the MAPT gene result in abnormal folding and aggregation of primarily 
3R tau, leading to aggregation and disease (Falcon, Zhang et al. 2018). Another 
tauopathy that has a far more relevant familial component, FTLD, involves 
autosomal dominant mutations in the MAPT gene in 10% of cases (Galimberti and 
Scarpini 2012). Additionally, abnormal phosphorylation such as at Asp421 can 
stimulate cleavage, rendering a truncated form of tau more prone to aggregation 
and tangle formation (Luna-Muñoz, Chávez-Macías et al. 2007). Beyond 
phosphorylation, a number of post-translational modifications (PTMs) are capable 
of alternating innate tau function and instigating pathology, including: acetylation, 
carboxy-terminal truncation, O-GlcNAcylation, and N-glycosylation (Congdon and 
Sigurdsson 2018). One role of hyperphosphorylated and oligomeric tau is in 
promoting the cell’s protein translational stress response. Pathologic tau leads to 
dysfunctional RNA binding proteins and regulation of stress granule assembly, 
which is implicated in multiple neurodegenerative disorders (Cruz, Verma et al. 
2019). 
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Chapter 1.2: Tau propagation and the Perforant Pathway 
 
One area of investigation in the study of AD is the “tau propagation 
hypothesis”. This hypothesis posits that the spread of tau pathology in the AD brain 
occurs through anatomically-connected regions and is facilitated inter-neuronally 
(Braak and Braak 1991, Kaufman, Del Tredici et al. 2018, Vogel, Iturria-Medina et 
al. 2019). Soluble tau is mainly bound to microtubules under physiological 
conditions, serving to stabilize them and promote polymerization. This interaction 
with microtubules is very dynamic, with tau binding and unbinding for milliseconds 
at a time (Janning, Igaev et al. 2014). In AD, the presentation of proteinopathic 
species occurs in a prototypical chronologic pattern throughout the progression of 
the disease. There are several proposed mechanisms of tau secretion: through the 
release of synaptic vesicles, secretion in extracellular vesicles such as exosomes, 
direct translocation across the membrane (free-form tau), or transport through 
tunneling nanotubes (Holmes, DeVos et al. 2013, Falcon, Noad et al. 2018). Tau 
can be taken up by cells via bulk endocytosis or macropinocytosis or phagocytosis 
(Zeineddine and Yerbury 2015, Das, Balmik et al. 2020). 
Over the past several years, many experiments have demonstrated in vivo 
as well as in vitro the potential for pathologic tau aggregates to propagate from 
afflicted cells to unafflicted cells. Frost et al revealed that fibrillar tau introduced to 
culture medium is endocytosed by cells preferentially compared to monomers, 
where it induces the fibrillization of endogenous full-length tau (Frost, Jacks et al. 
2009). Following these experiments, it was reported that tau trimers are the 
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minimal unit necessary to initiate propagation in seeded HEK293 cells and primary 
neurons (Mirbaha, Holmes et al. 2015). Many different studies have reported on 












Table obtained from (Takeda 2019)  
Table 1: Studies involving tau species and assessing propagation. 
Studies of tau propagation have involved the use of recombinant tau, tau derived from AD patient 
brains, tau-transgenic mice, as well as primary cell culture from AD patients. Monomers, oligomers, 










In addition to considering the polymerization state of pathologic tau, there 
are the different isoforms of tau to consider. Tau isoforms have distinct effects on 
PTMs such as phosphorylation, which affects the aggregation potential (Dinkel, 
Siddiqua et al. 2011, Despres, Byrne et al. 2017). Additionally, disease-causing 
polymorphisms in tau that cause disease such as those that lead to FTD are 
thought to alter the folding state of tau, leading to enhanced aggregation and 
seeding properties (Lewis, McGowan et al. 2000). Such mutations are the basis 
for animal models designed for investigating tauopathy and tau propagation, such 
as JNPL3 and PS19 mice (Lewis, McGowan et al. 2000, Yoshiyama, Higuchi et al. 
2007). In order to investigate tau propagation in vivo, soluble extracts from the 
dissected brain stem were isolated from PS19 mouse brains and injected 
intracranially into WT mice, which induced tau aggregation (Clavaguera, Bolmont 
et al. 2009). This was followed up with several other studies demonstrating the 
potential for assessing pathologic tau aggregation and propagation in vivo (de 
Calignon, Polydoro et al. 2012, Harris, Koyama et al. 2012, Liu, Drouet et al. 2012, 
Iba, Guo et al. 2013, Ahmed, Cooper et al. 2014). One study by Liu et al revealed 
a tendency for tau in the medial entorhinal cortex (MEC) to propagate to the 
dentate gyrus (DG) through the perforant pathway. 
The perforant pathway describes a series of connections between the 
entorhinal cortex and the DG, including all the Cornu Ammonis (CA) fields of the 
hippocampus. These include CA1, CA2, and CA3. Axons derived from neurons in 
the medial entorhinal cortex project to the outer molecular layer (OML) of the DG, 
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where they form synapses with distal dendrites from the granular cell layer (GCL). 
From there, sequential synaptic connections occur from the GCL to CA3, CA2, 
CA1, the Subiculum, and then back to the deeper layers of the MEC (Fig. 1) (Witter 
2007). Propagation of tau through the perforant pathway is supported by post-
mortem human brain examination as well as mouse models of tau propagation and 
likely occurs in both anterograde and retrograde fashion (Ahmed, Cooper et al. 
2014, Takeda 2019). This was accomplished through examining the location of tau 
pathology in human brains that are in different stages of AD progression. This 
suggests that prevention of tau propagation from the MEC may be a potential 
therapeutic route for halting the progression of the disease (Sigurdsson 2016). In 

















Figures obtained from Llorens-Martίn et al (Llorens-Martín, Blazquez-Llorca et al. 2014) and 
University of BRISTOL http://www.bristol.ac.uk/synaptic/pathways/ 
Figure 1: The hippocampal network and perforant pathway. 
(A) Input signals from the Entorhinal Cortex form connections with the DG and CA3 via the perforant 
pathway. Mossy Fibers (MF) deliver input from the DG to CA3. CA1 neurons receive input from 
CA3 via the Schaffer Collateral Pathway (SC) as well as the Associational Commissural Pathway 
(AC). From the CA1, the subiculum receives input and projects axons back to the entorhinal cortex. 




Chapter 1.3: Microglia and Neuroinflammation 
 
 Microglia are the innate immune cells of the central nervous system and 
possess many roles, including pruning of synapses, migrating towards and 
phagocytosing harmful material, releasing proinflammatory and anti-inflammatory 
cytokines, and assisting in neuronal growth through the release of neurotrophic 
factors among other functions (Prinz, Jung et al. 2019). It is speculated that 
microglia make up approximately 0.5-16.6% of all of the cells in the adult brain and 
the prevalence is highly dependent on the region of interest (Mittelbronn, K et al. 
2001). Microglia are differentiated from yolk-sac derived myeloid precursor cells. 
These progenitors of microglia infiltrate into the brain early in embryonic 
development and eventually mature early in the post-natal brain (Ginhoux, Greter 
et al. 2010). In their homeostatic state, microglia are constantly protruding and 
contracting their processes into the surrounding space while their soma remain 
stagnant (Fontainhas, Wang et al. 2011). 
 The brain undergoes a number of changes before reaching old age which 
lay the foundation for neurodegenerative disease development. There are several 
notable effects of aging on proteostasis in the CNS that lead to proteinopathy, 
which include: protein translation, PTMs, clearance, lysosomal degradation, 
phagocytic degradation, and proteasomal degradation (Kaushik and Cuervo 
2015). Microglia become dysfunctional is a result of old age as well, and undergo 
a number of functional changes such as decreased synaptic surveillance, 
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increased proliferation, a reduction in phagocytic capability, enhanced 
inflammatory cytokine secretion, and an overall less ramified morphology (Clayton, 
Van Enoo et al. 2017). Many if not all of these dysfunctional changes are 
speculated to influence disease development. Additionally, microglia in aged 
brains are more reactive to CNS and peripheral insults than microglia in relatively 
young brains (Godbout, Chen et al. 2005). 
 One of the most important characteristics of microglia pertains to their 
dynamic phenotypic roles, particularly in response to CNS insults. Microglia 
become activated through several different signaling pathways (Kaminska, Mota 
et al. 2016). Pathogen associated molecular patterns (PAMPs) as well as damage-
associated molecular patterns (DAMPs) initiate a cascade of signaling responses 
in microglia designed to address pathogenic threats or injury (Janeway 1992, 
Kigerl, de Rivero Vaccari et al. 2014). These are first perpetuated through pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) and nucleotide 
oligomerization domain (NOD)-like receptors (NLRs). When activated, microglia 
rapidly alter their morphology and function (Karperien, Ahammer et al. 2013). 
Differing states of activation of microglia subpopulations are a topic of much 
interest in recent years. Classically, these states of microglia activation were 
referred to as the M1 proinflammatory and M2 anti-inflammatory activation states 
of microglia. The former phenotype was characterized as being activated in 
response to proinflammatory molecules such as IFN-γ, TNFα, and LPS (Delgado 
and Ganea 2003) and would secrete many other proinflammatory cytokines as well 
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as reactive oxygen (ROS) and reactive nitrogen species (RNS). The M2 anti-
inflammatory microglial phenotype is described as responding to IL-4, IL-10, and 
TGFα, where they secrete neurotrophic factors such as IGF-1 and promote tissue 
repair in response to injury (Butovsky, Ziv et al. 2006). In addition to stimulating 
repair, microglia are also tasked with the removal of debris such as apoptotic 
neurons (Fig. 2). Recent transcriptomic studies enabling the examination of single 
microglial cells have revealed a large breadth and diversity of microglia 
subpopulations that appears to be heavily context specific (Masuda, Sankowski et 
al. 2020). Recently, a tendency to describe another form of microglia, one that is 
specific to the disease condition, has been utilized. A new classification of 
neurodegenerative disease microglia is changing the way researchers 








Figure adapted from (Clayton, Van Enoo et al. 2017) 
Figure 2: Microglia phagocytose and clear apoptotic debris. 
Activated microglia sense trace chemical signals and molecules from recently apoptotic cells and 
microglia towards their position. From there, they engulf the debris and begin to degrade it through 
lysosomal pathways. Aggregates that are not degraded intracellularly can be excreted through EVs 






Microglia recently have sustained much scrutiny due to the findings of 
genome-wide association studies (GWAS) in which a number of genes have been 
identified as significant risk factors for AD and other neurodegenerative diseases. 
A lot of these genes can be thought of as belonging to an immunoregulatory 
module and include APOE, TREM2, TYROBP, CD33, SHIP1 (Corder, Am et al. 
1993, Saunders, Strittmatter et al. 1993, Liu and Yu 2019). In the case of harmful 
proteinopathic species in neurodegenerative diseases such as Aβ plaques or 
NFTs, microglia retract their processes and adopt a more mobile, amoeboid 
morphology (Fontainhas, Wang et al. 2011). These microglia have enhanced 
chemotactic abilities, and migrate towards the proteinopathic insults. From there, 
they phagocytose the material and generate a barrier between it and the 
surrounding tissue. Recently, these have been referred to as “neurodegenerative 
microglia”, which is abbreviated as “MGnD” or “DAM”, and they have a particular 
set of characteristics (Keren-Shaul, Spinrad et al. 2017, Krasemann, Madore et al. 
2017). There are a number of differences between homeostatic, aged, and 















Figure adapted from (Clayton, Van Enoo et al. 2017) 
Figure 3: Microglia phenotypes influence function. 
Homeostatic microglia are the resting state of microglia under non-infectious and non-diseased 
conditions that have healthy or typical degrees of physiological function. They are characterized 
has having robust expression of homeostatic microglial markers (green). As the brain ages, 
microglia become dystrophic and lose some of their normal functionality and become more reactive. 
MGnD microglia lose much of their synaptic surveillance functions, proliferate frequently, and 







Generally, MGnD/DAM microglia are regarded as having a large reduction 
in their synaptic surveillance functions as well as their ramification. They also 
frequently proliferate, phagocytose material, and release proinflammatory 
cytokines in comparison to non-diseased microglia (Clayton, Van Enoo et al. 
2017). Additionally, like aged microglia, they are hyperreactive to insult (Yin, Raj 
et al. 2017). Further investigation of these microglia revealed they have a typical 
genetic signature, characterized by the upregulation of disease-associated 
markers and the downregulation of homeostatic markers, which is heavily 
regulated by ApoE, miR-155, and Triggering Receptor Expressed on Myeloid cells 
2 (TREM2) (Krasemann, Madore et al. 2017, Deczkowska, Keren-Shaul et al. 
2018). MGnD/DAM microglia can be identified via immunohistochemical (IHC) or 
immunofluorescence (IF) staining of Clec7a or Mac2 in afflicted brains of AD 
























Figure B adapted from (Keren-Shaul, Spinrad et al. 2017) 
 
Figure 4: MGnD induction in amyloid-bearing brains. 
(A) MGnD are elicited in response to amyloid pathology, as revealed by Clec7a (green) and Mac2 
(red) staining. MGnD can be seen in the cortex of 6-month-old APPNL-G-F mouse brains compared 
to there being little to none in WT brains. DAPI (blue) for nuclear counter-staining. (B) MGnD/DAM 










Although microglia activation is regarded as beneficial, indeed crucial, for 
restoring brain homeostasis in response to acute neuroinflammatory events such 
as traumatic brain injury or in response to pathogens, chronic microglial activation 
is regarded as harmful. The constant release of proinflammatory cytokines and 
reactive oxygen species or reactive nitrogen species (which are neurotoxic) by 
MGnD leads to self-perpetuating neuroinflammation, which prevents the brain from 
returning to healthy homeostasis (Polazzi and Monti 2010). It is believed that this 
chronic neuroinflammation serves to exacerbate neurotoxicity in response to 
proteinopathy, leading to quickened neuronal atrophy and neurodegeneration. 
Indeed, several studies have been published in the past several years indicating 
that preventing this phenotypic switch or eliminating microglia altogether has 
reduced overall Aβ deposition, p-tau development and propagation, and overall 
loss in brain volume/atrophy in neurodegenerative disease mouse models. One 
way in which this was achieved was through knock out (KO) of TREM2 in PS19 
mice, which dramatically reduced brain atrophy in comparison to control mice 
(Leyns, Ulrich et al. 2017). However, one study reported an opposite effect of 
TREM2 KO in hTau mice, where mice were characterized has having increased 
hyperphosphorylated tau compared to control (Bemiller, McCray et al. 2017). 
These hTau mice express only human tau and develop tau pathology after 9 
months (Andorfer, Kress et al. 2003). This suggests that the development of 
human tau pathology may be dramatically influenced by the presence of 
endogenous mouse tau. Particularly, when MGnD/DAM are impaired via genetic 
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deletion of TREM2, human tau pathology develops more rapidly. Researchers will 
likely continue to leverage the ApoE-TREM2 dynamic pathway for the modulation 
of MGnD/DAM phenotypes in the study of neurodegenerative disease.  
The emergence of the MGnD/DAM characterization of microglia has been 
accompanied by investigations into possible therapeutics strategies for modulating 
microglia phenotype to alleviate neurodegenerative disease. If the beneficial 
functional roles of MGnD can be enhanced while the detrimental aspects are 
suppressed, microglia can be modulated to be disease-modifying factors. One 
example of this would be the use of synthetic granulocyte-macrophage colony-
stimulating factor to enhance Aβ phagocytosis and clearance by microglia 
(Mitrasinovic, Perez et al. 2001). Another possibility is to use the phenomenon of 
monocyte infiltration in the brain to deliver genetically-modified cells into the CNS 
that have therapeutic properties. This idea stems from the observation that 
monocytes from the peripheral blood circulation are speculated only to infiltrate 
into the CNS in the diseased or injured brain condition, although this is a topic of 
controversy (Ginhoux, Greter et al. 2010, Bruttger, Karram et al. 2015). 
 
Chapter 1.4: Extracellular vesicles and microglia activation 
 
 Extracellular vesicles (EVs) possess many proposed functions. They are 
spherical vesicles, between 30 and 1000 nanometers in diameter, and are made 
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up of a lipid bilayer that are derived from cells. They are classically defined in three 
groups, exosomes, apoptotic bodies, and microvesicles. Exosomes are smaller 
than microvesicles and are defined as less than 150 nm in diameter. In contrast to 
microvesicles, exosomes are generated within multivesicular bodies (MVBs), 
which are the result of endosomal invaginations and are located within the 
cytoplasm. This process is regulated through the endosomal sorting complex 
required for transport or (ESCRT) proteins, which include proteins such as ALIX, 
HRS, or Tsg101. EVs are identified by the strong presence of tetraspanins such 
as CD9, CD63, and CD81, which is typically accomplished through immunoblotting 
(Théry, Witwer et al. 2018). EV size and morphology is most effectively determined 
through electron microscopy (EM). Exosomes are released into the extracellular 
space following exocytotic fusion of MVBs with the cellular membrane or are 
degraded following MVBs fusion with lysosomes. Microvesicles, on the other hand, 
are the result of direct budding of the cellular membrane. The cargo within EVs is 
very diverse, consisting of proteins, lipids, metabolites, nucleic acids, and 
organelles. EV release from cells is induced in response to activation via oxidative 
stress, cell death, inflammation, hypoxia, shear stress, or senescence among 
many other factors (Totani, Plebani et al. 2017, Shah, Patel et al. 2018, Kakarla, 
Hur et al. 2020). In AD, miRNAS, lysosomal proteins, synaptic proteins, and other 
contents of EV cargo are known to altered. Additionally, EVs from AD brains house 
cargo containing pathologic protein aggregates such as p-tau and Aβ (Lee, 
Mankhong et al. 2019). For this reason, they are investigated for their roles in 
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intercellular communication and signaling, which can be pertinent for disease 
development. In general, EVs can be viewed as shuttling vectors or signaling 
transducers that deliver cargo or information, and act as special regulators of 
communities of cells. 
 EVs are a subject of investigation for many different types of diseases. In 
cancer, EVs are believed to be released from cancerous cells and sent to 
neighboring tissues where they prime cells for tumor invasion and metastasis (Xu, 
Rai et al. 2018). EVs are also critical for regulating both the adaptive and innate 
immune responses (Robbins and Morelli 2014). The amplification of chemotactic 
recruitment of neutrophils is effectuated through packaged leukotriene B4 
(Majumdar, Tavakoli Tameh et al. 2016). In the CNS, EVs are secreted by dendritic 
cells, neurons, astrocytes, oligodendrocytes, and microglia (Mrowczynski, 
Zacharia et al. 2019). They are crucial for conducting common physiological 
processes such as maintaining synaptic plasticity and myelination. Following CNS 
injury, EVs appear to propagate inflammatory signals across the BBB as well as 
help facilitate neuroprotective and regenerative processes (Holm, Kaiser et al. 
2018). EVs derived from microglia have been documented to affect neuronal firing 
rate (Antonucci, Turola et al. 2012). The diverse and dynamic nature of EVs 
suggests they are worthy of investigation in the disease context. 
 EV cargo can reflect the disease status in cells from which they are derived. 
For this reason, investigators are attempting to and have had some success in 
developing biomarker assays in which EVs are collected from either the blood or 
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cerebral-spinal fluid in order to diagnose diseases such as AD, chronic traumatic 
encephalopathy (CTE), cancer, liver, autoimmune, atherosclerosis, viral 
transmissibility, and many other disease areas (Lapitz, Arbelaiz et al. 2018, 
Simeone, Bologna et al. 2020, Muraoka, Jedrychowski et al. 2021). In 
neurodegenerative diseases such as AD, Parkinson’s disease (PD), and 
amyotrophic lateral sclerosis (ALS), many different biomarkers are being 
investigated that are derived from plasma and CSF EVs. For AD, some prominent 
candidates are P-T181/P-S396 (phosphorylated tau), Aβ, neurogranin (NRGN), 
restricted silencing factor (REST), cathepsin D, Lysosomal-associated membrane 
protein 1 (LAMP-1), heat-shock protein 70, a myriad of microRNAs, as well as 
many other potential markers (Yuan, Li et al. 2019). These efforts to identify EV 
biomarkers may be more effective in the future when tissue-specific EVs can be 
easily investigated. Additionally, EVs are being investigated as possible delivery 
vessels for therapeutics given that they are likely to produce limited side-effects 
while being highly specific and can carry a diverse body of cargo (Aryani and 
Denecke 2016). Their hydrophilic cores make them ideal carriers of water-soluble 
drugs (Jiang and Gao 2017). With regards to neurodegenerative diseases, EVs 
are found to play an emerging role in their pathogenesis, propagation, and 
progression.  
In AD, EVs are known to carry portions of the toxic aggregates, senile 
plaques and NFTs (Iranifar, Seresht et al. 2019). Monomeric and oligomeric forms 
of both Aβ and tau can be found within AD-derived EVs (Polanco, Li et al. 2018, 
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Ruan, Pathak et al. 2020).  Exosome markers are found in human and mouse brain 
slices, suggesting that they may be involved in the transport and sequestration of 
toxic Aβ (Quek and Hill 2017). This finding was expanded upon when it was found 
that plasma-derived whole exosomes congregated around Aβ plaques (Zheng, 
Zhang et al. 2017). One study found that Aβ induces the secretion of exosomes 
that contain ceramide through a neutral sphingomyelinase 2 (nSMase2)-
dependent pathway and this lead to the apoptosis of astrocytes (Wang, Dinkins et 
al. 2012). Additionally, the contents of AD patient-derived exosomes induce 
neuronal apoptosis. Propagation of pathologic p-Tau through anatomically 
connected regions in the mouse CNS through exosomes was recently reported 
and was seemingly dependent on microglia (Asai, Ikezu et al. 2015). It is also 
possible that EVs are necessary for mediating neuroprotective responses to AD, 
such as promoting the capture and clearance of Aβ by microglia (Yuyama, Sun et 
al. 2015). Neuroprotective proteins like cystatin C were also demonstrated to be 
secreted by neurons through exosomes. Loss of the neuroprotective effects of 
Cystatin C-containing EVs is hypothesized to be a mechanism by which Presenilin 
2 mutations lead to the pathogenesis of the disease (Ghidoni, Paterlini et al. 2011). 
 
Chapter 1.5: Specific Aims 
 
Given that microglia have an apparent role in mediating the toxic effects of 
neuroinflammation, which is involved in the manifestation and propagation of tau 
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pathology, we hypothesized that enhanced secretion of tau-seeding EVs from AD-
affected microglia exacerbates tauopathy. 
 
Aim 1: Determine the consequence of microglia depletion on amyloid pathology. 
Aim 1.1: Quantify the degree of microglia depletion following 2 months of 
administration of the potent CSF1R inhibitor and microglial poison, PLX5622. 
Aim 1.2: Assess the effect of PLX5622 treatment on plaque pathology in the 
APPNL-G-F mouse model. Specifically, determine if microglia are necessary for 
plaque compaction and if depletion leads to an overall increase in plaque presence 
in the brain. Additionally, examine any differences of effect on dense-core, fibrillar 
plaque compared to diffuse plaque pathology. 
Aim 1.3: Determine the effect of microglia depletion on broader neuroinflammation 
in the WT and APPNL-G-F brain. 
Aim 2: Determine the consequence of microglia depletion on tau pathology and 
its propagation. 
Aim 2.1: Evaluate the effect of microglia depletion on tau propagation in cells from 
the medial entorhinal cortex to the granular cell layer of the dentate gyrus. 
Additionally, investigate the effect of tau propagation to CA1 and the polymorph 
(Hilus) regions. 
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Aim 2.2: Investigate the presence of plaque-associated p-tau aggregation in brains 
injected with AAV-P301L-tau in the APPNL-G-F mouse model.  
Aim 3: Examine the potential of MGnD microglia to secrete extracellular vesicles. 
Aim 3.1: Determine if MGnD microglia express elevated levels of tetraspanins and 
other EV-associated markers compared to homeostatic microglia. 
Aim 3.2: Examine in vivo the tendency of MGnD to over-secrete EVs compared to 
homeostatic microglia. 
Aim 3.3: Determine if microglia secrete EVs that contain p-tau. 
Chapter 2: Microglia surround and compact amyloid plaques 
 
Chapter 2.1: Experimental design and rationale 
 
 One of the means by which researchers can investigate the role of microglia 
is through their selective depletion from the CNS via pharmacologic intervention or 
genetic intervention. This is achieved through the use of colony-stimulating factor 
1 receptor (CSF1R) inhibitors such as PLX5622, GW4869, JNJ-40346527, and 
PLX3397 (Table 2) (Dagher, Najafi et al. 2015, Spangenberg, Severson et al. 
2019, Ali, Mansour et al. 2020). CSF1R is a single pass type I membrane receptor 
that acts as the receptor for colony-stimulating factor 1, which is a cytokine that 
controls the production, differentiation, and function of macrophages. Constant 
stimulation of CSF1R is required for microglia survival (Lei, Cui et al. 2020). 
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Treatment with potent CSF1R inhibitors results in near complete depletion of 
microglia within one week (Elmore, Najafi et al. 2014, Asai, Ikezu et al. 2015, 
Dagher, Najafi et al. 2015, Spangenberg, Lee et al. 2016). By removing nearly all 
microglia within a specified timeframe in mouse models of neurodegenerative 
disease, we can better understand what their role is in the pathological progression 
of disease. Many studies have been published within the last decade utilizing one 
form of microglia depletion or another to investigate the effect on disease 
pathology, particularly mouse models of amyloid or tau pathology, which have 
amounted to mixed and interesting results. It was first reported through 
administration of ganciclovir in APP/CD11b-HSVTK mice that microglia depletion 
had no effect on plaque formation or neuritic dystrophy (Grathwohl, Kälin et al. 
2009). Several subsequent studies published similar results of microglia depletion 
through a myriad of techniques on overall plaque load in amyloid-bearing mouse 
models (Dagher, Najafi et al. 2015, Olmos-Alonso, Schetters et al. 2016, 
Spangenberg, Lee et al. 2016, Zhong, Xu et al. 2019). However, one mouse model 
in particular, the 5xFAD model, consistently seemed to produce the result that 
plaque burden was significantly alleviated following microglia depletion 
(Spangenberg, Severson et al. 2019, Casali, MacPherson et al. 2020). 
Additionally, microglia depletion appeared to sequester Aβ to the blood vessels, in 
an apparent display of cerebral amyloid angiopathy. This demonstrates that 
microglia can be important not only for the clearance and compaction of amyloid 
plaques, but also their localization and fibrilization properties. Interestingly, plaque-
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associated microglia have been reported to be more sensitive to CSF1R inhibition-
mediated depletion compared to homeostatic microglia (Zhao, Hu et al. 2017). 
Treatment with PLX3397 for two months did not produce any cognitive 
abnormalities in mice (Elmore, Najafi et al. 2014). CSF1R inhibition is not without 
its off-target effects, affecting macrophage function and hematopoiesis among 
other peripheral considerations (Lei, Cui et al. 2020). 
 
Chapter 2.2: Methods 
 
2.2.1 Animals, PLX5622 administration, and genotyping 
 
Mouse housing and experimental procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) of Boston University School 
of Medicine. APPNL-G-F mice were bred and genotyped in house. Mice were housed 
with their own sex in a barrier facility practicing a 12-h light/dark cycle. Food and 
water were provided ad libitum. Experiments were conducted with a roughly equal 
male to female population representation. Animals were under the constant care 
and watch of veterinary staff. Mice were genotyped via PCR (Saito, Matsuba et al. 
2014) with the following primers: E16WT: 5’ – ATCTCGGAAGTGAAGATG – 3’ 
E16MT: ATCTCGGAAGTGAATCTA WT: 5’ – TGTAGATGAGAACTTAAC – 3’ 
loxP: 5’ – CGTATAATGTATGCTATACGAAG – 3’. 
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Two mouse groups were utilized for the study, the amyloid-bearing APPNL-
G-F mouse model, and the standard C57BL/6 mouse model. PLX5622-containing 
chow or control chow (Plexxikon, Inc., San Francisco, CA) was administered to 
mice ad libitum through infusion into chow (AIN-76A, Research Diet, Inc., 
Brunswick, NJ) at 1200 mg/kg beginning at 4 months of age (Fig. 5). Investigators 
were blinded to food treatment condition. Following 2 months of PLX5622 
treatment, animals were anesthetized prior to being sacrificed via transcardial 
























Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 5: Study design for PLX5622-mediated microglia depletion. 
(A) Study design of PLX5622-mediated microglia depletion. Mice are administered 1200 mg/kg 
PLX5622 ad libitum in chow for 2 months beginning at 4 months and are sacrificed at 6 months of 






2.2.2 Histological Processing, immunofluorescence staining, and 3D image 
rendering analysis 
 
Following sacrifice, brains were subsequently fixed with 4% 
paraformaldehyde (PFA) at 4°C overnight under gentle agitation. The next day, 
brains were immersed in 30% sucrose under gentle agitation in preparation for 
cryosectioning. Brains were encased in optimal cutting temperature compound 
(OCT) before being sectioned at 30 µm intervals in a Cryostat NX50 (Themofisher 
Scientific, #957250K) before being stored in cryoprotectant. 
For immunofluorescence, sections were generally stained in free-floating 
fashion. The following antibodies and reagents were utilized: 4G8 1:100 (Aβ 17-
24, BioLegend, #800704), thioflavin-S 1:50 in 50% ethanol (Sigma, #T1892-25G), 
GFAP 1:300 (Cell Signaling Bio, #36705), 82E1 1:100 (Aβ 1-16, IBL, #10323). 
Rabbit polyclonal anti-mouse P2RY12 antibody 1:600 was generously provided by 
Oleg Butovsky’s laboratory (Butovsky, Jedrychowski et al. 2014, Butovsky, 
Jedrychowski et al. 2015). For antigen retrieval, sections were immersed in 88% 
formic acid for 3 minutes. Prior to staining, sections were blocked with blocking 
solution, which consisted of 5% normal goat or donkey serum, 5% bovine serum 
albumin (BSA), and 1% Triton X-100. All following primary and secondary antibody 
staining was conducted using 5% BSA, 1% Triton in PBS as the staining buffer. 
After staining completion, slices were mounted on Superfrost plus microscope 
slides (Thermo Fisher Scientific, #22-037-246) and allowed to dry at room 
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temperature. Coverslip glass was applied using Fluoromount G (Invitrogen, #00-
4958-02). Tiled images for regional analysis of Aβ deposition were taken 20X with 
an Eclipse Ti microscope (Nikon Instruments). For regional quantification, tiled 
images were observed and processed using the open-source image processing 
package FIJI, which can automatically quantify the size, circularity, and number of 
plaques. Confocal z-stack images for plaque morphology were taken using an SP8 
Confocal Microscope with Lightning (Leica). Processing of z-stack images was 
conducted using IMARIS rendering software (Oxford Instruments). Each z-stack 




Statistical analyses were carried out using GraphPad Prism v8 (Graph-Pad 
Software, Inc). For comparisons between two groups, unpaired t-tests assuming 
equal variances were used. For comparisons between four experimental groups, 
Two-way ANOVA was used and normal distributions were assumed when making 
post-hoc analyses while correcting for multiple comparisons (Tukey). 
 
Chapter 2.3: Results 
 
35 
Chapter 2.3.1: Microglia are depleted via administration of CSF1R inhibitor 
 
 Treatment of mice with 1200/ mg/kg PLX5622 resulted in an overall ~92% 
reduction in microglia number (Fig. 5). Extent of microglia depletion was quantified 
via reduction in P2RY12 staining. P2RY12 is a marker for homeostatic microglia 
(van Wageningen, Vlaar et al. 2019). Depletion was evident in both WT and APPNL-
G-F mice following 2 months of PLX5622 treatment. Near-complete depletion was 
expected for the vast majority of the 2 months given that PLX5622-mediated 
microglia depletion is evident following only 1 week of treatment (Fig. 6) (Lehmann, 
Weigel et al. 2019). No adverse effects of PLX5622 treatment were noted over the 






















Figure adapted from (Clayton, Delpech et al. 2021) and (Lehmann, Weigel et al. 
2019) 
Figure 6: Microglia depletion in WT and APPNL-G-F brains. 
(A) Representative image of P2RY12 staining in WT or APPNL-G-F brains following PLX5622 or 
control chow treatment. (B) Microglia depletion is ~92% in both WT and APPNL-G-F mice following 2 
months of PLX5622 administration assessed by reduction in P2RY12 staining. (C) PLX5622-
infused chow depletes microglia nearly completely within 14 days of administration (view of the 
DG). Data were subject to two-way ANOVA. * represent p <0.05 between indicated groups and ## 







Chapter 2.3.2: Plaque compaction by microglia is evident following microglia 
depletion via Thioflavin S and 4G8 staining, but not 82E1 staining 
 
 In order to assess the effect of microglia depletion on plaque compaction as 
well as overall amyloid deposition, staining of Thioflavin S, 4G8, and 82E1 was 
conducted. Firstly, plaque compaction was evaluated via quantifying the average 
circularity of Thioflavin-S+ plaques (Fig. 7A). Next, the overall Thioflavin S+ area, 
average plaque size, and average number of plaques was quantified. Microglia 
depletion resulted in a marked reduction in plaque circularity, indicating that 
microglia-mediated plaque compaction was inhibited following PLX5622 treatment 
(Fig. 7B). The overall Thioflavin S+ area was significantly increased following 
microglia depletion. Additionally, the average plaque size and average number of 
plaques saw statistically significant increases as well. Most notably, plaque 
number was increased by nearly 50%. Z-stack images and 3D renderings of 
individual dense core plaques revealed a large increase in average plaque volume 
and surface area with a marked decrease in average plaque sphericity (Fig. 7 C-



















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 7: Microglia depletion results in reduced plaque compaction, increased plaque 
number and size. 
(A) Representative image of Thioflavin S+ plaques in APPNL-G-F brains following PLX5622 or control 
chow treatment. (B) Quantification of plaque circularity, plaque size, number, and overall Thioflavin-
S+ area. (C) Representative 3D rendering image of Thioflavin S+ plaques. (D) Quantification of 





In addition to affecting dense-core plaque pathology, microglia depletion 
had several effects on diffuse plaque pathology as well. Staining with 4G8, which 
detects residues 17-24 of the Aβ peptide, revealed that microglia depletion leads 
to a statistically significant increase in the overall 4G8+ area as well as the average 
size of 4G8+ plaques (Fig. 8 A-B). However, when examining plaque 
characteristics using a different marker, 82E1, microglia depletion did not appear 
to have any effects (Fig. 8 C-D). 82E1 targets residues 1-16 of the Aβ peptide and 
stains with a pattern that is distinct from 4G8 (Fig. 8 E). Taken together, these data 

























Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 8: Microglia depletion results in greater plaque size and overall area when 
evaluated via 4G8 staining, but not 82E1 staining. 
(A) Representative image of 4G8+ plaques in APPNL-G-F brains following PLX5622 or control chow 
treatment. (B) Quantification of plaque circularity, plaque size, number, and overall 4G8+ area. (C) 
Representative image of 82E1+ plaques in APPNL-G-F brains following PLX5622 or control chow 
treatment. (D) Quantification of plaque circularity, plaque size, number, and overall 4G8+ area. (E) 
Representative 3D rendering of 4G8+ and 82E1+ plaque displaying distinct staining patterns. * 





Chapter 2.2.3: Astrogliosis is unaffected by microglia depletion 
In order to evaluate the broader effects of microglia depletion on overall 
neuroinflammation in the CNS, we decided to examine astrocyte activation. 
Astrogliosis describes a state of astrocyte activation that is often characteristic of 
neurodegenerative diseases (Li, Li et al. 2019). Glial fibrillary acidic protein (GFAP) 
is a maker for astrogliosis and commonly expressed by astrocytes in the AD brain, 
generally in close proximity to amyloid plaques (Nagele, J et al. 2004, Li, Li et al. 
2019). When staining for GFAP in WT as well as APPNL-G-F brains, astrogliosis was 
evident in APPNL-G-F, but missing in WT brains as expected (Fig. 9A-B). 
Additionally, PLX5622-mediated microglia depletion had no effect on astrogliosis. 
















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 9: Amyloid plaques trigger astrogliosis, which is unaffected by microglia depletion. 
(A) Representative image of GFAP+ astrocytes in WT and APPNL-G-F brains following PLX5622 or 
control chow treatment. (B) Quantification of astrogliosis as overall GFAP+ area. **** represents p 












Chapter 2.3: Discussion 
 
Several possibilities could describe the discrepancy witnessed of microglia 
depletion on Aβ when evaluating with Thioflavin S, 4G8, and 82E1. Firstly, 
Thioflavin S is a fluorescent dye that binds to beta-sheet rich amyloid fibrils among 
other dense-fibrillar aggregates, but not individual monomers of Aβ (Bussière, 
Bard et al. 2004). Therefore, Thioflavin S stains mainly the dense core portion of 
Aβ plaques whereas 4G8 and 82E1 can target individual Aβ monomers and 
present with a much larger, more diffuse pattern. Microglia may preferentially 
target dense-core fibrillar regions of Aβ plaques for phagocytosis rather than 
diffuse monomer/oligomer portions, and therefore the effects of microglia depletion 
are most easily observed via Thioflavin S staining. To explain the inconsistency 
between 4G8 and 82E1 staining, it is important to understand these two antibodies 
are markers for distinct amyloid species. P3 is the peptide product of non-
amyloidogenic cleavage by α-secretase (Fig. 10). Although not considered 
pathogenic itself, P3 is nonetheless a large constituent of Aβ plaques in the AD 
brain (Higgins, Murphy et al. 1996). In addition to staining for Aβ, 4G8 will also 
stain for P3, thus allowing for visualization of the portions of Aβ plaques that are 
comprised of P3 while 82E1 does not allow for this. Therefore, if microglia 
depletion affects mainly portions of Aβ plaques comprised primarily of P3, we will 
see an effect of PLX5622 treatment only through 4G8 staining and not through 
82E1 staining. Or 4G8 may simply be more sensitive in detecting the effects of 
microglia depletion because it stains for both P3 and Aβ. 
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Figure adapted from (Varnum 2015) 
Figure 10: APP can be processed through non-amyloidogenic (top) or through 






There are many studies of microglia depletion involving mouse models of 
amyloid deposition (Table 2). Most studies report microglia depletion (using 
multiple mechanisms) did not ultimately influence the degree of amyloid aggregate. 
However, other results have been varied, either suggesting microglia depletion 
exacerbates or even alleviates amyloid deposition. Although most report no effect, 
a substantial minority of studies suggest that microglia depletion, particularly in the 
5XFAD mouse model, is very effective at reducing plaque burden. To date, only 
one short-term study has reported microglia depletion to exacerbate amyloid 
burden (Zhao, Hu et al. 2017).  
A number of different reasons could explain the variability of results in 
studies of microglia depletion in amyloid-bearing mice. Firstly, the methods for 
evaluating the effect of microglia depletion on Aβ deposition and compaction vary 
(Table 2). As demonstrated in Figure 8, the specific markers used for quantification 
can be the difference between witnessing a large effect and no effect at all. 
Secondly, the mouse models themselves are different and consistent of different 
mutations causing plaque build-up. As mentioned previously, the 5XFAD mouse 
model seems to have a unique response to microglia depletion in that it 
substantially alleviates deposition, and this is the only model in which this effect 
has been reported. Lastly, the degree of microglia depletion, age at onset, and 
time period of microglia depletion vary widely between the different models, which 
are bound to affect the outcome. In the future, some consolidation of these different 
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considerations should be made to generate a more rigorous understanding of the 






Table obtained from (Clayton, Delpech et al. 2021) 
Table 2: Studies involving amyloid-bearing mice and microglia depletion. 
Studies of microglia depletion in amyloid-bearing mice are numerous, but rarely reach consensus. 
Studies are conducting with a myriad of microglia depletion techniques and assess the effects in 
many different ways. Some studies have reported positive effects on amyloid pathology in 5xFAD 
mice (bright green), no effects on amyloid pathology (dark green), or exacerbated effects on 
amyloid pathology (beige). 
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Chapter 3: Pathologic tau propagation from the MEC to the DG of the 
Hippocampus is exacerbated in a mouse model of Alzheimer’s disease and 
corrected via PLX5622 treatment 
 
Chapter 3.1: Experimental design and Rationale 
 
 Neurofibrillary tangles first develop in the MEC in the AD brain and spread 
to the DG and other areas in a stereotypical pattern as stated previously (Braak 
and Braak 1991, Braak, Alafuzoff et al. 2006). Therefore, it is of particular interest 
for AD researchers to investigate the process by which this propagation occurs 
and if there are possible therapeutic interventions that could halt the spread of the 
pathology. In order to study the propagation of tau, researchers resort to a myriad 
of in vitro and in vivo methodologies. Yet, models that mirror the specific 
propagation of tau from relevant anatomically-connected regions are the most 
likely to possess translational potential. For this reason, we developed the rapid 
tau propagation model involving injection of AAV2/6 pseudotyped synapsin-1 
promoter-driven transgene expression of P301L MAPT mutant (AAV-P301L-tau) 
(Asai, Ikezu et al. 2015). Injection of AAV-P301L-tau into the MEC induces strong 
expression of p-Tau, which propagations to the GCL of the DG in a matter of 
weeks.  
The P301L mutation in the MAPT gene is an autosomal dominant missense 
mutation that leads to frontotemporal lobar degeneration (FTLD) (Hutton, Lendon 
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et al. 1998). Upon post-mortem examination, patients with the P301L mutation 
present with intracytoplasmic tau aggregates within neurons and glia in the 
hippocampus, neocortex, and substantia nigra. Severe neurodegeneration and 
gliosis are evident in these patients (Spillantini, Ra et al. 1998). The mutation 
occurs within the highly conserved exon 10 region of the MAPT gene and therefore 
only affects the 4-repeat tau isoform (Fig. 11). (Dumanchin, A et al. 1998). For 
these reasons, the P301L mutation was selected to induce pathologic tau in the 
rapid tau propagation model. AAV-P301L-tau produces robust p-tau deposition 












Figure 11: Schematic diagram of six tau isoforms expressed in humans.  
There are alternatively spliced exons 2 (blue), 3 (red), and 10 (arrow). The P301L mutation lies 
within exon 10 and affects mainly the 4-repeat tau isoform and greatly enhances its aggregation 








In order to investigate the interplay between tau pathology propagation and 
amyloid pathology, we decided to investigate rapid tau propagation in both WT 
mice and APPNL-G-F mice. The APPNL-G-F mouse model possesses 3 familial AD 
mutations that produce robust amyloid deposition in the brain starting at 2 months 
of age (Saito, Matsuba et al. 2014). This mouse is a knock-in model of the human 
APP and therefore expresses endogenous levels of the gene as opposed to 
transgenic mouse models. The NL (Swedish) mutations result in greater cleave of 
APP by beta-secretase while the G mutation increases the aggregation rate of Aβ, 
and the F mutation produces longer isoforms of Aβ through reduced cleavage of 
gamma-secretase (Saito, Matsuba et al. 2014). Following one month 
administration (beginning at 4 months of age) of PLX5622 or control chow, 
injection of AAV-P301L-tau into the MEC (coordinates AP: 4.75, ML: 2.90, 
DV:4.64) of APPNL-G-F and WT mice at 5 months of age was conducted to induce 





















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 12: The perforant pathway connects the MEC to the DG.  
(A) The perforant pathway runs from layer 2 in the MEC to the DG, CA3, and CA1, in that order. 
(B) AAV-P301L-tau is injected into the MEC of 5 month-old mice at coordinates (AP: 4.75, ML: 





Chapter 3.2: Methods 
 
3.2.1 Animals, PLX5622 administration, and genotyping 
 
Approval by the IACUC, acquisition of APPNL-G-F mice, animal housing, 
genotyping, and veterinary care were all carried out as described in Chapter 2. 
C57BL/6 mice were acquired from the National Institute of Aging (NIA). Two mouse 
groups were utilized for the study, the amyloid-bearing APPNL-G-F mouse model 
(whose background in the C57BL/6 mouse), and the standard C57BL/6 mouse 
model. PLX5622 or control (Plexxikon, Inc., San Francisco, CA) was administered 
to mice ad libitum through infusion into chow (AIN-76A, Research Diet, Inc., 
Brunswick, NJ) at 1200 mg/kg beginning at 4 months of age. Investigators were 
blinded to food treatment condition. Following 2 months of PLX5622 treatment, 
animals were anesthetized and sacrificed via transcardial perfusion with 
phosphate-buffered saline (PBS). 
 
3.2.2 Histological Processing and immunofluorescence staining 
 
Brain harvesting, preparation for sectioning, collection of brain slices, and 
storage were all carried out as previously described in Chapter 2. For 
immunofluorescence, sections were generally stained in free-floating fashion. The 
following antibodies and reagents were utilized: 4G8 1:100 (Aβ 17-24, BioLegend, 
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#800704), 82E1 1:100 (Aβ 1-16, IBL, #10323), AT8 1:300 (Ser202/Thr205 p-Tau, 
ThermoFisher Scientific, #MN1020). Antigen retrieval, blocking, staining 
conditions, mounting on slides, imaging, and image processing were all carried out 
as previously described in Chapter 2.  
 
3.2.3 Viral Production and Intracranial Injection of AAV-P301L-tau 
 
Our AAV-P301L-tau construct expresses the mutant version (P301L) of 
human tau under the syn-1 promoter. The syn-1 promoter is specific to neurons 
(Kügler, Meyn et al. 2001). Approximately 1 µl of AAV-P301L-tau was injected into 
the MEC during intracranial injection surgery. The titer of this virus is approximately 
1.2 x 1011. Surgery was carried out using a robotic stereotaxic device which 
incorporated both a drill and microinjection machine (Neurostar, Tubingen, 
Germany). The syringe used for surgery was a 10-µl Hamilton (model 701 LT, 
#80301) with 1 mm glass capillary, which were held together by a microelectrode 
holder (World Precision Instruments #MPH6S10). For aseptic surgery, mice were 
anesthetized for surgery using 3% isoflurane. To manage pain, mice received 15 
mg/kg meloxicam prior to the surgery. Any animals experiencing undue trauma or 
distress following injections were sacrificed and excluded from the study. The viral 




All statistical analyses for two group and four group comparisons were 
carried out as described in Chapter 2. 
Chapter 3.3: Results 
 
3.3.1: Tau propagation is enhanced by amyloid plaque pathology and 
reduced via microglia depletion 
 
 In order to assess the propagation of p-Tau from the medial entorhinal 
cortex (MEC) to the granular cell layer (GCL) of the dentate gyrus (DG), 
immunofluorescence against AT8 was conducted. Strong AT8+ signal was 
witnessed in the MEC as well as the GCL of the DG following one month’s viral 
incubation (Fig. 13A). Firstly, we noted there was a dramatic increase in the 
propagation rate, nearly 10-fold AT8+ signal, between WT mice and APPNL-G-F mice 
that received the control chow (Fig. 13B). This demonstrates that amyloid plaque 
deposition serves to bolster the seeding potential of p-tau between anatomically-
connected regions. Additionally, there was a substantial reduction in tau 
propagation following PLX5622 administration in both the WT and APPNL-G-F 
groups. This suggests that p-tau propagation is heavily influenced by the actions 
of microglia, considering that their selective depletion the propagation rate. AT8 
stains for both human and mouse phosphorylated tau. In order to assess the 
propagation rate of human tau derived from AAV-P301L-tau expression, staining 
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was conducted with the HT7 antibody, which produced the same tendency, but 
was not significant (Fig. 14A). Tau propagation was witnessed as far as 0.8 mm 
medially from the injection point (Fig. 14B). In addition to the GCL, p-tau 
propagation from the MEC to the to the Hilus and CA1 regions of the DG was also 




























Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 13: Quantification of tau propagation from the MEC to the GCL of the DG.  
(A) Representative image of strong somal staining of AT8 in the MEC and GCL of the DG. (B) 
Unbiased quantification of AT8+ propagation rates from the MEC to the GCL. Propagation is 
calculated as the density of AT8+ cells in the GCL divided by the same in the MEC. Tau propagation 





















Figure 14: Tau propagates from the MEC to the GCL of the DG.  
(A) Unbiased quantification of HT7+ propagation rates from the MEC to the GCL. Tau propagation 
values across all 4 treatment groups are displayed. (B) Propagation from 2.90 mm lateral from 





































Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 15: Tau propagates from the MEC to the Hilus and CA1 regions  
(A) AT8+ cells were seen in the Hilus and CA1 of injected brains. (B) Unbiased quantification of 
propagation rates from the MEC to the Hilus and CA1 regions of injected rbains.. Tau propagation 









 Several studies of microglia depletion and tau propagation have been 
conducted in recent years (Table 2). The studies have mixed reporting on the 
effect of microglia depletion on tau pathology of propagation, split between 
microglia reduced overall tau pathology or propagation of tau pathology and having 
no effect at all. Most studies involve the use of the PS19 mouse model, but also 
















Figure adapted from (Clayton, Delpech et al. 2021) 
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Chapter 3.4: Discussion 
 
Aβ plaques dramatically increased the rate of propagation from 
anatomically-connected regions when comparing tau propagation between WT 
and APPNL-G-F mice under identical treatment conditions. Ablation of microglia 
through PLX5622 treatment in AAV-P301L-tau injected APPNL-G-F mice 
significantly suppressed propagation of tau from the MEC to the GCL to levels 
observed in WT mice. This effect was demonstrated via staining with AT8, which 
recognizes both human and mouse phosphorylated tau. However, this was not 
evident when staining for HT7, and overall tau pathology was not as robust. We 
believe this is because much of the mutant human P301L tau may serve as 
seeding factors for endogenous mouse tau, and therefore seeding propagation will 
be evident mostly when staining for AT8 and suggests most AT8 signal 
corresponds to mouse tau.  
There are many possible explanations for how Aβ plaques could exacerbate 
tau propagation from the MEC to the GCL. Although it was previously reported that 
tau pathology is exacerbated by Aβ deposition (Li, Braunstein et al. 2016, He, Guo 
et al. 2017), it has not been so clearly dependent on the actions of microglia until 
now. This is because we were able to selectively deplete virtually all microglia in 
the brain. We previously established that microglia depletion curtails tau 
propagation in WT and PS19 mice in a manner that was seemingly dependent on 
EVs (Asai, Ikezu et al. 2015). Given this context, we naturally hypothesize that Aβ 
are perhaps accentuating the spread of tau through EVs derived from microglia 
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(Fig. 15). Particularly, there is a class of microglia in the amyloid-bearing brain that 































Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 15: Diagram of Aβ plaque deposition and microglia-mediated tau propagation from 
the MEC to the GCL of the DG. MGnD (generated by Aβ plaques) are postulated to exacerbate 
tau propagation.   
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Chapter 4: Pathologic tau deposition on amyloid plaques is exacerbated 
following microglia depletion 
 
Chapter 4.1: Experimental design and Rationale 
 
 Tau pathology can manifest in several different forms depending on the 
disease. Neurofibrillary tangles are the most prominent tau pathology and are 
characteristics hallmarks for AD, CTE, Primary age-related tauopathy PART, and 
FTD among others. Other tau-related pathologies manifest in neurodegenerative 
diseases such as ballooned inclusion bodies in Pick’ disease and corticobasal 
degeneration (Forman, Zhukareva et al. 2002). Tau pathology manifests as 
argyrophilic grains and coiled bodies in Argyrophilic grain disease (Ferrer, 
Santpere et al. 2008). Recently the characterization was made of a new form of 
tau pathology that manifests as p-Tau+ and plaque-associated voxels (He, Guo et 
al. 2017, Leyns, Gratuze et al. 2019). This tau pathology is referred to as “NP tau”, 
and is characterized mainly in the APPNL-G-F mouse model and is also found in 
human AD brain slices (He, Guo et al. 2017). Although NP tau is only described in 
experiments involving injection of human-derived sarkosyl-insoluble tau, p-tau+ 
dystrophic neurites are characteristic of the APPNL-G-F model inherently, making 
them ideal for the study of NP tau. The distinction between NP Tau and p-tau+ 
dystrophic neurites is not explicit as both are identified via p-tau staining.  
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 The APPNL-G-F mouse model is conventionally used in the characterization 
of NP Tau. Additionally, TREM2 KO in APPNL-G-F mice injected with sarkosyl-
insoluble hTau was recently found to dramatically increase both the development 
and inter-hemisphere propagation of NP Tau (Leyns, Gratuze et al. 2019). TREM2, 
which heavily mediates the phenotypic switch of microglia from homeostatic to 
MGnD, was particularly relevant for exacerbating NP Tau pathology. Given that 
TREM2 KO confers a somewhat loss of function of microglia, we thought it 
pertinent to investigate the effects of total microglia depletion on the manifestation 
of NP Tau. Additionally, the characterization of NP Tau in a mouse model involving 
injection of AAV expressing mutant human tau has not been conducted. We sought 
to investigate if adenovirus expressing pathologic human tau could elicit the same 
pathology in APPNL-G-F mice and whether or not microglia depletion would affect 
the extent to which the pathology developed.  
 
Chapter 4.2: Methods 
 
 4.2.1 Animals, PLX5622 administration, and genotyping 
 
Approval by the IACUC, acquisition of APPNL-G-F mice, animal housing, 
genotyping, and veterinary care were all carried out as described in Chapter 2. 
C57BL/6 mice were acquired from the National Institute of Aging (NIA). Two mouse 
groups were utilized for the study, the amyloid-bearing APPNL-G-F mouse model, 
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and the standard C57BL/6 mouse model. PLX5622 or control (Plexxikon, Inc., San 
Francisco, CA) was administered to mice ad libitum through infusion into chow 
(AIN-76A, Research Diet, Inc., Brunswick, NJ) at 1200 mg/kg beginning at 4 
months of age. Investigators were blinded to food treatment condition. Following 2 
months of PLX5622 treatment, animals were sacrificed via transcardial perfusion 
with phosphate-buffered saline (PBS). 
 
4.2.2 Histological Processing and immunofluorescence staining 
 
Brain harvesting, preparation for sectioning, collection of brain slices, and 
storage were all carried out as previously described in Chapter 2. For 
immunofluorescence, sections were generally stained in free-floating fashion. The 
following antibodies and reagents were utilized: 4G8 1:100 (Aβ 17-24, BioLegend, 
#800704), 82E1 1:100 (Aβ 1-16, IBL, #10323), AT8 1:300 (Ser202/Thr205 p-Tau, 
ThermoFisher Scientific, #MN1020). Antigen retrieval, blocking, staining 
conditions, mounting on slides, imaging, and image processing were all carried out 
as previously described in Chapter 2.  
 
4.2.3 Viral Production and Intracranial Injection of AAV-P301L-tau 
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Approvals and procedures for carrying out aseptic survival surgery in mice 
were conducted as previously described in Chapter 3. Production of the AAV-
P301L-tau virus was conducted as described in Chapter 3. 
4.2.4: Statistics 
All statistical analyses for two group and four group comparisons were 
carried out as described in Chapter 2. 
 
Chapter 4.3: Results 
 
 4.3.1: NP Tau deposition is increased following microglia depletion 
 
 After injection of AAV-P301L-tau into the MEC of 5-month-old APPNL-G-F 
mice and following one month’s viral incubation, AT8+ and plaque-associated 
voxels resembling NP Tau were observed as predicted (Fig. 16A). Additionally, 
following PLX5622-mediated microglial depletion, there was a measurable 
increase in the NP Tau deposition observed on amyloid plaques within the MEC 
(Fig. 16B). A similar study was conducted in which AD tau extracts were injected 
into APPNL-G-F mice where TREM2 was knocked out. This resulted in a dramatic 
increase in the build-up and propagation of NP Tau (Leyns, Gratuze et al. 2019). 
In addition to the MEC, NP Tau deposition on amyloid plaques in the SLM, Hilus, 
and OML regions of the hippocampus were also quantified. Here, there appeared 
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to be a similar tendency for NP Tau deposition to increase as in the MEC, although 

































Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 16: NP Tau forms as result of AAV-P301L-tau injection into APPNL-G-F mice.  
(A) Representative images of NP Tau deposition following injection into APPNL-G-F mice receiving 
no injection, AAV-P301L-tau injection, and AAV-P301L-tau injection with PLX5622 treatment. (B) 
Quantification of AT8+ plaque area to assess degree of NP tau development. * represents p < 0.05 











Figure 17: Quantification of NP Tau in the OML, Hilus, and SLM following administration of 
control chow or PLX5622-containing chow. NP Tau is quantified as the percentage of the 
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Chapter 4.4: Discussion 
 
 Examination of a specific manifestation of p-tau aggregation, NP Tau, 
demonstrated that injection of our AAV-P301L-tau yielded a significant increase in 
its deposition compared to mice that have not been injected. This suggests that 
the expression of hyperphosphorylated and misfolded mutant tau is capable of 
producing NP tau. Additionally, depletion of microglia yielded a large increase in 
NP Tau deposition. This suggests that microglia could be important not only for the 
propagation of tau, but how p-tau is sequestered and aggregated. One reason for 
this is activated and plaque associated MGnD are likely phagocytosing NP Tau, 














Chapter 5: MGnD microglia release increased amounts of tau-bearing 
extracellular vesicles  
 
Chapter 5.1: Experimental design and Rationale 
 
MGnD are a recently characterized form of disease-associated microglia 
known to possess unique phenotypic characteristics compared to homeostatic 
microglia, and these characteristics are likely relevant to the neuroinflammation-
mediated exacerbation of AD. One of such characteristics is the propensity to 
hyper-phagocytose material marked for consumption, such as Aβ, pathologic tau, 
and apoptotic neurons among others. When such material is phagocytosed, the 
propensity for microglia to release undigested material through EVs is evident 
(Clayton, Delpech et al. 2021). In addition to phagocytosing proteinopathic 
species, microglia are also heavily engaged in synaptic pruning (Hong, Dissing-
Olesen et al. 2016). We believe this makes microglia particularly relevant when 
investigating the propagation of p-tau along anatomically-connected regions in AD 
and other diseases. If in addition to being hyper-phagocytic, MGnD hyper-secrete 
EVs, this could dramatically enhance the propensity for proteinopathic species to 
seed pathology in distal regions. These two-phenomenon coupled together could 
provide a compelling case for targeting MGnD as a potential therapy for AD and 
other neurodegenerative diseases to halt their progression in afflicted patients.  
74 
In order to assess whether or not MGnD are hyper-secreting EVs, we 
continued to examine the APPNL-G-F mouse in comparison to WT mice as they 
possess prominent MGnD induction in the relevant brain regions (Fig. 4A). First, 
we decided to test if MGnD visually colocalized strongly with any prominent EV 
markers, such as tetraspanins. In addition to immunofluorescence staining, MGnD 
and homeostatic microglia can be separately harvested from the APPNL-G-F brain, 
allowing for ex vivo assessment of transcriptomic properties of these distinct 
microglia populations. Lastly, in order to examine the release of microglia-specific 
EVs in vivo, we engineered a lentiviral construct to express the prominent CD9 
tetraspanin conjugated to fluorescent mEmerald reporter (mE-CD9). This lentivirus 
was then injected into both APPNL-G-F mice as well as WT mice in order to examine 
EV secretion by MGnD in comparison to homeostatic microglia. 
 
Chapter 5.2: Methods 
 
 5.2.1 Animals, PLX5622 administration, and genotyping 
 
Approval by the IACUC, acquisition of APPNL-G-F mice, animal housing, 
genotyping, and veterinary care were all carried out as described in Chapter 2. 
C57BL/6 mice were acquired from the National Institute of Aging (NIA). Two mouse 
groups were utilized for the study, the amyloid-bearing APPNL-G-F mouse model, 
and the standard C57BL/6 mouse model. PLX5622 or control (Plexxikon, Inc., San 
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Francisco, CA) was administered to mice ad libitum through infusion into chow 
(AIN-76A, Research Diet, Inc., Brunswick, NJ) at 1200 mg/kg beginning at 4 
months of age. Investigators were blinded to food treatment condition. Following 2 
months of PLX5622 treatment, animals were sacrificed via transcardial perfusion 
with phosphate-buffered saline (PBS). 
 
5.2.2 Histological Processing and immunofluorescence staining 
 
Brain harvesting, preparation for sectioning, collection of brain slices, and 
storage were all carried out as previously described in Chapter 2. For 
immunofluorescence, sections were generally stained in free-floating fashion. The 
following antibodies and reagents were utilized: 4G8 1:100 (Aβ 17-24, BioLegend, 
#800704), 82E1 1:100 (Aβ 1-16, IBL, #10323), AT8 1:300 (Ser202/Thr205 p-Tau, 
ThermoFisher Scientific, #MN1020), 1A5 1:300 (GFP, Santa Cruz #sc-101536), 
DAPI 1:2500 (Thermo Fisher Scientific, #62248), C1q 1:300 (Abcam, #ab182451), 
Tsg101 1:300 (Santa Cruz Biotech, #sc-7964), anti-Mac2/Galectin (R&D systems, 
#AF-1197), Clec7A 1:100 (InvivoGen, #mabg-mdect). Antigen retrieval, blocking, 
staining conditions, mounting on slides, imaging, and image processing were all 
carried out as previously described in Chapter 2, with the exception of when 
staining for GFP, there was no antigen retrieval used. Quantification of mE-CD9+ 
voxels was done through the use of IMARIS rendering software (Oxford 
Instruments). Z-stacks were taken of individual microglia, each of which was 50 
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µm by 50 µm and whose thickness was approximately 30 µm. All voxels in close 
proximity to individual microglia were assumed as being derived from that 
microglia. 
 
5.2.3 Viral Production and Intracranial Injection of AAV-P301L-tau 
 
Approvals and procedures for carrying out aseptic survival surgery in mice 
were conducted as previously described in Chapter 3. Production of the AAV-
P301L-tau virus was conducted as described in Chapter 3. 
5.2.4 Microglia Isolation and cell sorting 
 
In order to obtain Clec7a+ and Clec7a- microglia, mice were transcardially 
perfused with ice-cold Hanks Balanced Salt Solution (HBSS) and whole brains 
were harvested. Cortical brain tissue was then dissected into 1 cubic millimeter 
squares and homogenized into single cell solution in ice cold HBSS with a glass 
Dounce homogenizer. Following homogenization, the single cell suspension was 
centrifuged over a 37% to 70% discontinuous Percoll solution (GE Healthcare). 
After centrifugation, mononuclear cells were collected via pipette from the 37%-
70% interphase. Fluorescence-activated cell sorting (FACS) was carried out by 
institutional technicians to isolate microglia. Forward and side scattering allowed 
for exclusion of doublet cells. Dead cells were excluded via staining with DRAQ7 
(Novus Biologicals, #NBP2-81126). Microglia were distinguished from myeloid 
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cells via FCRLS staining. FCRLS is expressed on microglia, but not myeloid cells 
infiltrating into the CNS (Butovsky, Jedrychowski et al. 2014, Krasemann, Madore 
et al. 2017). Additionally, microglial cells were identified via staining for CD11b and 
Ly6C to further purify the microglia population. Lastly, the microglia cells were 
separated as MGnD or homeostatic depending on being either Clec7a +/-. 
 
5.2.5: Isolation of RNA, synthesis of cDNA, and quantitative polymerase 
chain reaction (qPCR) 
 
In order to purify microRNA and total RNA from purified MGnD and 
homeostatic microglia, the miRNeasy Mini Kit (Qiagen, #217004) was utilized 
according to provided manufacturer protocols. To generate cDNA, the Superscript 
VILO cDNA synthesis kit (Thermo Fisher Scientific #11754050) was used. 100 ng 
of RNA was used following digestion with DNase I (Ambion, # AM2222). qPCR 
was carried out in a total volume of 6 µl. The reaction volume for each test 
contained 0.5 µl of primers (Thermo Fisher Scientific, #4331182), 1 µl of Taqman 
Fast Advanced Master Mix (Thermo Fisher Scientific, #4444557), 1.5 µl of cDNA, 
and 3 µl of water. The amplification was conducted using an Abi Prism 7900HT 




5.2.6: Lentivirus production 
 
The pLV-EF1α-mEmerald-CD9-miR9T lentivirus was generated by 
modifying commercially available pLV.PGK.GFP.miR9T lentivirus (Åkerblom, 
Sachdeva et al. 2013). The EF1α promoter was inserted into the 
pLV.PGK.GFP.miR9T vector while mEmerald was conjugated to the 5’ end of the 
gene for human CD9. Additionally, miR9T was added to the 3’ UTR to ensure 
microglia-specific expression (Åkerblom, Sachdeva et al. 2013). The mEmerald-
CD9 fusion was a gift from Michael Davidson (Addgene plasmid # 54029 ; 
http://n2t.net/addgene:54029 ; RRID:Addgene_54029). To generate high-quality 
and high-titer lentivirus, production and packaging was conducted by SignaGen 
Laboratories (Rockville, MD USA). The viral titer is over 1E + 9 TU/ml. To achieve 
in vivo lentiviral transduction, 1 µl of lentivirus was injected into the MEC 
coordinates (AP: 4.75, ML: 2.90, DV: 4.64) of 6 month-old APPNL-G-F and C57BL/6 
mice. Following injection, viral incubation lasted for 10 days before animals were 
euthanized and brains harvested for analysis. 
 
5.2.7: Cell culture transduction 
 
For viral plasmid transfection and transduction in vitro, human embryonic 
kidney 293 T cells (HEK293T) were cultured in 24-well tissue culture plates for 24 
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hours prior to experimentation. The culture media was composed of Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen #11965118), 1% penicillin-
streptomycin (P/S, Thermo Fischer Scientific, #15140122), and 10% fetal bovine 
serum (FBS, Thermo Fischer Scientific, #A3382001). HEK293T cells were serum 
starved for one hour prior to transduction with 1 µl of mE-CD9 lentivirus or control 
lentivirus. 
 
5.2.8: Western Blotting 
 
HEK293T cells were cultured in 24-well plates and transfected with the pLV-
EF1α-GFP-miR9T or pLV-EF1α-mEmerald-CD9-miR9T plasmid. 2.5 µg of 
mEmerald-CD9 lentiviral plasmid was transfected into cells using Lipofectamine 
3000 reagent (Thermo Fisher Science, #L3000008) in Opti-MEM (Themo Fisher 
Scientific, #51985091). Transfection media was replaced with 1% PS and 10% 
FBS DMEM following the first 24 hours of transfection. Cells were allowed to 
express plasmid contents for 3 days following transfection. The conditioned media 
was then collected and EVs were purified via sequential centrifugation. The 
centrifugation proceeded as follows: 2,000 × g for 30 min, 10,000 × g for 30 min, 
at 144,000 × g for 70 min. The final pellet was collected and resuspended as the 
EV-containing fraction. To lyse cells and EVs, RIPA buffer (Thermo Fisher 
Scientific, #89901) containing Halt Protease and Phosphatase inhibitor Cocktail 
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(Thermo Fisher Scientific, #78442) was used with vortexing. Samples were then 
prepared for western blot (WB) by immersion into Laemmli Sampling buffer (Bio-
Rad, #S3401-10VL) containing 2% v/v 2-mercaptoethanol at 95 degrees Celsius 
for 5 minutes. Samples were loaded into lanes, 10 µg each as evaluated by 
PierceTM Bicinchoninic acid assay (BCA) (Thermo Fisher Scientific, #23225) and 
subjected to 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis 
(SDS-PAGE). Following electrophoresis, bands were transferred to polyvinylidene 
difluoride (PVDF) membrane (Bio-Rad, #1620177). The membrane was blocked 
with 3% skim milk in Tris-buffered saline (TBS) containing 5% Tween20 (Sigma 
Aldrich, #93773). Membranes were then stained with anti-GFP antibody at 1:500 
dilution (Santa Cruz Biotec, B-2) for detection of mEmerald overnight at 4 degrees 
Celsius. Membranes were thoroughly washed with TBS containing 5% Tween 20 
prior to incubation with HRP-conjugated anti-mouse secondary antibody at 
1:10,000 dilution (Cell Signaling Technology, #7076) for one hour at room 
temperature. Following further washing with TBS containing 5% Tween 20, protein 
bands were detected with Immobilion chemiluminescent HRP substate (Millipore 
Sigma, #WBKLS0100) and visualized with Chemiluminescent Western Blot 




5.2.9: EV isolation from whole brain tissue and mEmerald ELISA 
  
 Isolation of EVs from mouse brains was carried out in the following order: 
dissection, dissociation, homogenization, sequential centrifugation, and finally 
sucrose gradient ultracentrifugation (Muraoka, DeLeo et al. 2020, Muraoka, Lin et 
al. 2020). Brains were first minced on ice with a razor into very fine pieces and 
then resuspended into Hibernate E media (Gibco/Thermo Fisher Scientific, 
#A1247601) containing 10 units of Papain (Worthington-biochemical corporation, 
#LK003178) to be digested at 37 degrees Celsius for 15 minutes with occasional 
stirring. Following digestion, brains were homogenized via 20 strokes in a glass 
Dounce homogenizer. After homogenization, brains are subjected to sequential 
centrifugation in the following order: 300 x g for 10 minutes, 2,000 x g for 10 
minutes, and 10,000 x g for 10 minutes. The supernatant was collected and used 
for each successive centrifugation while the pellet was discarded. Next, the 
supernatant from the final centrifugation was filtered through a 0.22 µm hydrophilic 
polyethersulfone (PES) filter (EMD Millipore, #SLGP033RS) prior to 
ultracentrifugation at 140,000 x g for 70 minutes. Afterward, the pellet was 
resuspended in 0.475M sucrose and carefully dispensed on top of a density 
sucrose gradient. The entire gradient was then spun in the ultracentrifuge at 
200,000 x g for 20 hours. The 0.650M and 0.800M fractions were then collected 
and further spun down at 140,000 x g for 70 minutes to purify the EVs. Isolated 
EVs were then lysed with RIPA buffer (Thermo Fisher Scientific, #89901) with 
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vortexing for 15 minutes and subjected to GFP ELISA (Abcam, #ab171581) to 
quantify mEmerald concentration.  
 
 5.2.10: Statistics 
 
All statistical analyses for two group and four group comparisons were 
carried out as described in Chapter 2. A simple linear regression was conducted 
on CD9 voxel release and Mac2+ staining intensity to establish a correlation. 
 
Chapter 5.3: Results 
 
5.3.1: ESCRT protein Tsg101 colocalizes with disease-associated MGnD 
marker 
  
 Activated MGnD congregate around and phagocytose Aβ plaques (Fig. 
4A). When staining for MGnD using Clec7a as well as the prominent ESCRT 
pathway protein, Tsg101, we discovered a strong colocalization between these 
two markers (Fig. 18A). The ESCRT pathway is heavily involved in the biogenesis 
and release of EVs (Colombo, Moita et al. 2013). Additionally, when examining the 
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injected portion of the MEC, we discovered a significantly greater density of MGnD 





























Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 18: MGnD and Tsg101 in the APPNL-G-F mouse brain.  
(A) Representative z-stack image of the colocalization of Clec7a and Tsg101 in close association 
with amyloid plaques. (B) Quantification of the presence of MGnD in the MEC of virus-injected 
brains. (C) Quantification of Clec7a in the 4G8+ area within the MEC of injected APPNL-G-F brains. 
(D) Quantification of Tsg101 in the 4G8+ area of injected APPNL-G-F brains. ** represents p < 0.01 











 In order to assess the potential for EV secretion in WT and APPNL-G-F mouse 
brain, the Tsg101 signal needed to be quantified. Animals treated with PLX5622 
saw a large reduction in the Clec7a+ signal associated with 4G8+ plaque signal 
(Fig. 18A&C), indicating that the PLX5622 treatment reduced the number of 
plaque associated MGnD. In accordance with the reduction of MGnD, there was a 
large reduction in plaque-associated Tsg101+ signal following treatment with 
PLX5622 (Fig. 18 D). Tsg101 signal was not present in homeostatic (Clec7a-) 
microglia (Fig. 19A). Additionally, we sought to investigate the propensity of 
plaque-associated MGnD microglia to phagocytose NP Tau. High-resolution 
confocal Z-stack images and renderings showed that AT8+ and plaque-associated 
p-tau appeared to be encapsulated by plaque-associated MGnD microglia (Fig. 



















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 19: MGnD microglia colocalize with Tsg101 and internalize NP tau.  
(A) Representative images of homeostatic (Clec7a-) and MGnD (Clec7a+) microglia colocalizing 
with Tsg101. (B) Representative image of plaque-associated MGnD (Mac2+) microglia 
encapsulating NP tau. FSB (blue) stains for dense-core plaques, AT8 (red) stains for p-tau, and 







5.3.2: Engineered lentivirus expresses mEmerald fused to the N-terminus 
of CD9 specifically in microglia following in vivo injection into the MEC 
 
Although when staining for MGnD in the amyloid-bearing brain we see clear 
colocalization of EV machinery marker, Tsg101, this does not demonstrate extra 
EVs are released by MGnD in comparison to homeostatic microglia. Therefore, we 
sought to develop a means with which EV release by microglia could be examined 
in vivo. For this, we engineered the mE-CD9 lentivirus to monitor microglia-specific 
release of EVs in vivo (Fig. 20A). mEmerald is fused to the N-Terminus of human 






































ATG – mEmerald start codon 
GTGAGC – mEmerald sequence 
AAG – A206K mEmerald mutation 
TCCGGAC – 10 amino acid linker sequence 
CCGGTC – human CD9 sequence 
TAG – CD9 stop codon 
 
Figure 20: pLV-EF1α-mEmerald-CD9-miR9T lentivirus.  
(A) Schematic of the mE-CD9 lentivirus with EF1α promoter, mEmerald-CD9 fusion protein, and 
miR-9T for microglia-specific expression. (B) Sequence of mEmerald-CD9 fusion protein. 
B 
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Following lentivirus engineering and packaging, the mE-CD9 plasmid was 
transfected into HEK293T cells. 3 days after transfection, strong mEmerald signal 
was present (Fig. 21A). After imaging, secreted EVs were purified from the culture 
medium via sequential centrifugation. The whole cell lysate as well as EV fraction 
were lysed and subjected to SDS-Page for immunoblot detection of mE-CD9. Both 
mEmerald and the mE-CD9 fusion protein were detected while the fusion protein 
was most highly concentrated in the EV fraction (Fig. 21B). This suggests that 
CD9 is mostly sequestered to EVs. The mEmerald band is likely the result of 
cleavage of the protein linker between mEmerald and CD9. To ensure our 
engineered lentivirus expresses mE-CD9 specifically in microglia when injected in 
vivo, we injected 1 µl of packaged virus into the MEC of WT mice and allowed for 
10 days of viral incubation. We found following anti-GFP and Iba1 staining that the 
mE-CD9 protein was detected only when overlapping with Iba1+ signal (Fig. 21C). 



















Figure adapted from (Clayton, Delpech et al. 2021) 
 
 
Figure 21: pLV-EF1α-mEmerald-CD9-miR9T lentiviral plasmid exhibits strong expression 
and is microglia-specific. 
(A) Representative images of mEmerald fluorescence after control or mE-DC9 plasmid were 
transiently transfected into HEK293T cells. (B) Representative image of WB against mEmerald 
(GFP) indicating presence of mE-CD9 fusion protein. (C) Representative image of MEC stained for 
GFP, and Iba1 + P2RY12 in brain injected with mE-CD9 lentivirus following 10-day incubation. 
Quantification showed ~94% overlap between mE-CD9 signal with Iba1 + P2RY12. 
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5.3.3: Lentivirus-infected and disease-associated microglia release more 
extracellular vesicles than homeostatic microglia 
 
The mE-CD9 lentivirus allows for monitoring of microglia-specific EV 
secretion in vivo. To determine if MGnD microglia, as indicated by Mac2 staining, 
are secreting more EVs than homeostatic microglia, we injected the mE-CD9 
lentivirus into the MEC (AP: -4.75, ML: 2.90, DV: 4.64) of both APPNL-G-F and WT 
mice. In order to observe EVs released by individual microglia, z-stack images 
were taken of individual microglia that were designated as either homeostatic WT, 
homeostatic APPNL-G-F, or MGnD APPNL-G-F (Fig. 22A-B). Rendering of microglia 
z-stacks allowed for quantification of mE-CD9+ particles released by individual 
microglia (Fig. 22C). MGnD appeared to release substantially more EVs compared 
to homeostatic microglia in either APPNL-G-F or WT mice, almost three times as 
much (Fig. 22D). To demonstrate that the MGnD phenotype, which can be partial 
or complete, is responsible for the increase in EV release, a linear regression 
plotting Mac2 signal intensity against the amount of mE-CD9+ particles released 
revealed a strong correlation between the two (Fig. 22E). To corroborate the idea 
that MGnD are releasing more EVs in comparison to homeostatic microglia, the 
left hemispheres of brains (injection of mE-CD9 lentivirus was bilateral) were 
isolated and their EVs purified through sequential centrifugation and sucrose 
gradient (Fig. 23A). GFP ELISA of isolated EVs revealed a high sequestration of 















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 22: MGnD secrete more EVs than homeostatic microglia.  
(A) Depiction of lentivirus construct. (B) Representative tiled image of mE-CD9 expression in the 
MEC following 10 days incubation. (C) Representative z-stack images and renderings of EV 
release in homeostatic (Mac2-) microglia and MGnD (Mac2+).  (D) Quantification of mE-CD9+ 
particle release from individual microglia (n=12 each). (E) Linear regression and trendline 
correlating Mac2 signal intensity with mE-CD9+ particle release. ** represents p < 0.01 between 













Figure adapted from (Muraoka, Lin et al. 2020) and (Clayton, Delpech et al. 2021) 
Figure 23: EVs are isolated from APPNL-G-F and WT brains injected with mE-CD9 lentivirus. 
(A) Schematic process of EV isolation from mouse brain tissue. (B) GFP ELISA of EV fractions 









 5.3.4: MGnD isolated from APPNL-G-F mouse brains express more EV 
markers compared to homeostatic microglia 
 
 Given that MGnD appear to be releasing more EVs compared to 
homeostatic microglia in vivo, MGnD should be expressing more EV-related 
markers such as tetraspanins than homeostatic microglia. In order to examine 
whether or not MGnD express more EV-related markers, Clec7a+/- microglia were 
isolated from 6 month-old APPNL-G-F mice via FACS (Fig. 24). Following collection 
of Clec7a+ and Clec7a- populations of microglia, RNA was purified from each 
group to synthesize cDNA. qPCR was conducted for prominent tetraspanins CD9, 
CD81, CD63, as well as Tsg101, C1Qa, and ApoE (Fig. 25). ApoE, which is 
drastically upregulated in MGnD compared to homeostatic microglia (Krasemann, 
Madore et al. 2017), experienced an over 20-fold increase in expression in the 
MGnD compared to homeostatic microglia. Additionally, two EV-related markers, 
CD9 and CD63, were significantly overexpressed in MGnD compared to 
homeostatic microglia. These data suggest MGnD are expressing these molecules 




















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 24: MGnD and homeostatic microglia are isolated from 6-month-old APPNL-G-F mice.  
Dead cells and doublet cells are first removed, followed by selection markers for all microglia. 
Lastly, microglia are collected as two populations, Clec7a+ and Clec7a-. MGnD are Clec7a+ 










Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 25: MGnD express two prominent tetraspanins, CD9 and CD63, more than 












5.3.5: MGnD microglia are induced by AAV-P301L-tau expression and 
secrete p-tau within their EVs 
 
Pathologic p-tau propagates from the MEC to the hippocampus through 
several proposed mechanisms. If disease-associated microglia are able to excrete 
p-tau seeds through their EVs, this should be visible in vivo. To examine the 
presence of p-tau in microglia-specific EVs in the mouse brain, mE-CD9 lentivirus 
along with AAV-P301L-tau were bilaterally injected into the MEC of both WT and 
APPNL-G-F mice. Beginning at 4 months, mE-CD9 was injected into the MEC, 
following by 1 month of incubation before injection of AAV-P301L-tau in the same 
region (Fig. 26A). Immunofluorescence staining of double-injected brains revealed 
that mE-CD9 expressing microglia were interacting directly with p-tau in the 
injected region (Fig. 26B). P-tau+ and mE-CD9+ EVs are witnessed in both WT 
and APPNL-G-F mice. Many of these p-tau interacting microglia were MGnD 
microglia, as indicated by their Mac2-positivity. This reveals that microglia can 
phenotypically shift from homeostatic to MGnD microglia in response to tau 
pathology and not only amyloid pathology.  
Z-stack confocal images and renderings of Mac2+/- microglia revealed that 
both homeostatic and MGnD microglia were simultaneously phagocytosing p-tau 
and excreting EVs (Fig. 26C). This suggests microglia’s effect on tau pathology is 
derived from both homeostatic and MGnD microglia. Additionally, as quantified 
before, the amount of EVs released per microglia was quantified for Mac+/- 
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microglia in both WT and APPNL-G-F groups (Fig. 26D). In both animal groups, 
MGnD microglia released significantly more EVs than their homeostatic 
counterparts. This suggests that Aβ and tau pathology can elicit the same 
phenotypic response in microglia that causes enhanced secretion of EVs. The 
amount of tau internalized by individual Mac2+/- microglia was also quantified, 
which revealed that MGnD microglia internalize p-tau more than homeostatic 
microglia (Fig. 26E). Lastly, the amount of p-tau internalized within EVs specifically 
from individual microglia was quantified (Fig. 26F). Quantification demonstrated 
that the amount of p-tau encapsulated within microglia-specific EVs was higher 
from MGnD microglia compared to homeostatic microglia.  
In order to demonstrate p-tau encapsulation by microglia-specific EVs, high-
resolution renderings of Z-stacks of individual microglia were taken. Further 
magnification of renderings unveiled the presence of p-tau directly encapsulated 
by EVs derived from the microglia (Fig. 27A). The amount of p-tau within EVs and 
their corresponding sizes was highly variable. To verify the presence of p-tau within 
EVs, double immunogold electron microscopy was utilized. This technique allowed 
for direct visualization of p-tau encased within microglia-specific EVs, which were 
positive for both AT8 and mE-CD9 (Fig. 27B). Although in both WT and APPNL-G-F 
mice, MGnD microglia are induced as a result of tau pathology, the response is 
higher in APPNL-G-F compared to the former (Fig. 28). All together, these data 
demonstrate that MGnD microglia, in response to tau pathology, secrete more tau-













Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 26: Double-injection of mE-CD9 lentivirus and AAV-P301-tau in WT and APPNL-G-F 
mice.  
(A) Timeline of injection and incubation of mE-CD9 lentivirus and AAV-P301L-tau. (B) 
Representative images of mE-CD9 and AAV-P301L-tau injection into the MEC. (C) Representative 
Z-stack confocal images and renderings of mE-CD9+/Mac2+/- microglia interacting with p-tau. (D) 
Quantification of EV secretion by mE-CD9+/Mac2+/- microglia in WT and APPNL-G-F mice. (E) 
Quantification of p-tau phagocytosed by mE-CD9+/Mac2+/- microglia in WT and APPNL-G-F mice. (F) 
Quantification of p-tau encapsulated by mE-CD9+ EVs released from mE-CD9+/Mac2+/- microglia 
in WT and APPNL-G-F mice. * represents p < 0.05 between indicated groups. # represents p < 0.05 
for the Mac2 factor. ## represents p < 0.01 for the Mac2 factor. 
 










Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 27: Pathologic p-tau is encapsulated within microglia-specific EVs.  
(A) High magnification renderings of p-tau within microglia-specific EVs of various sizes. (B) 
Electron microscopic images of EV slices double-labelled for AT8 (5 nm) and GFP (10 nm) showing 


















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 28: Quantification of percentage Mac2+ area in the MEC in WT and APPNL-G-F mice 
following 1 month incubation of AAV-P301L-tau injection. * represents p < 0.05 between indicated 









5.3.6: Microglia tag synapses in the outer molecular layer with C1Q in 
APPNL-G-F mice more so than WT mice. 
 
 C1Q is a protein complex that is an integral part of the complement system. 
Synapses are tagged with C1Q for phagocytosis in the OML of the DG (Stephan, 
Madison et al. 2013, Dejanovic, Huntley et al. 2018). In the CNS, C1Q is mostly 
derived from microglia (Fonseca, Chu et al. 2017). C1Q+ signal in the OML of 
APPNL-G-F mice was higher than that of WT mice (Fig. 29A). Additionally, PLX5622-
mediated depletion of microglia led to a statistically significant reduction in C1Q 

















Figure adapted from (Clayton, Delpech et al. 2021) 
Figure 29: C1Q-mediated synaptic tagging in the OML.  
(A) Representative images of C1Q staining in the OML in WT and APPNL-G-F mice. (B) Quantification 
of C1Q signaling intensity in the OML across the four experimental groups. * represents p < 0.05 















Chapter 5.4: Discussion 
 
In this chapter, we present data to suggest that MGnD are hypersecreting 
EVs and that those EVs include pathologic p-tau. MGnD may be relevant to 
mediating the spread of tau from anatomically-connected regions because they 
are not observed in non-diseased brain. As we witnessed in chapter 3, tau 
propagation is exacerbated greatly in APPNL-G-F mice compared to WT. 
Therefore, the presence of MGnD in APPNL-G-F mice may be particularly 
relevant to the increased propagation of p-tau observed in this model. As 
demonstrated in Figure 18, MGnD are a much more significant factor in APPNL-
G-F mice in the MEC compared to WT. Additionally, PLX5622 treatment reduced 
MGnD prevalence back to WT levels. This observation, coupled with previous 
knowledge of how microglia-derived EVs mediate tau propagation from the MEC 
to the DG (Asai, Ikezu et al. 2015), led us to investigate whether or not MGnD are 
a subtype of microglia with enhanced EV secretion properties. 
The first piece of evidence to suggest enhanced EV secretion was the 
potent colocalization of MGnD with Tsg101. Tsg101’s main role is in the ESCRT 
pathway (Ferraiuolo, Manthey et al. 2020). The dramatic increase in Tsg101 
presence within MGnD suggests they are producing more EVs, even though we 
did not observe Tsg101 mRNA to be overexpressed via qPCR. We believe this 
means that although Tsg101 may not be overexpressed, it is nonetheless 
accumulated in MGnD compared to homeostatic microglia, perhaps because it is 
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more necessary for EV secretion and is diverted away from autophagic processes 
that would clear it from the cell. qPCR of tetraspanins revealed CD9 and CD81 to 
be overexpressed in MGnD compared to homeostatic microglia. Upregulation of 
EV-associated markers in MGnD suggests they are over-producing EVs. This was 
demonstrated most conclusively using the novel lentivirus expressing mE-CD9 in 
MGnD as well as homeostatic microglia. By examining release of EVs into the 
extracellular space by individual microglia, we gain valuable insight into their rate 
of EV secretion. Greater mE-CD9+ particle presence surrounding MGnD 
compared to homeostatic microglia strongly suggests enhanced EV release.  
Lastly, we were able to couple our utilization of the mE-CD9 lentivirus and 
AAV-P301L-tau to observe p-tau encapsulation directly within microglia-specific 
EVs. Following injection of both viruses, we witnessed MGnD microglia induced 
by p-tau pathology in WT and APPNL-G-F mice, although this was more prevalent 
in the later. However, both homeostatic and MGnD microglia that were mE-CD9+ 
were observed responding to tau pathology. By quantifying the degree of EV 
release in the microglia, we revealed that MGnD secrete more EVs than their 
homeostatic counterparts. Most importantly, these EVs contained that pathologic 
p-tau within them, suggesting their potential to seed p-tau in distal areas. If Aβ 
serves to potentiate the phenotypic shift of microglia to MGnD, this provides a 
mechanism for how tau propagation is exacerbated in the amyloid-bearing brain 
through the release of p-tau-containing microglial EVs.  
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Chapter 6: Novel Renilla luciferase drug screening platform identifies 
inhibitor hits for Triggering Receptor Expressed on Myeloid cells 2 
 
Chapter 6.1: Experimental design and Rationale 
 
TREM2 is a transmembrane signaling receptor that is potently expressed 
in microglia and whose mutations are potent risk factors for AD and other 
neurodegenerative diseases (Kober, Alexander-Brett et al. 2016). TREM2 
regulates activation, phagocytosis, as well as cytokine release in microglia 
(Poliani, Wang et al. 2015). Expression of TREM2 is upregulated in AD patient 
brains  (Lue, Schmitz et al. 2015, Celarain, Sánchez-Ruiz de Gordoa et al. 2016, 
Ma, Allen et al. 2016, Perez, Nadeem et al. 2017). The TREM2 signaling cascade 
is dependent upon successful coupling of TREM2 to its adaptor protein, TYRO 
protein tyrosine kinase-binding protein (TYROBP). Homozygous loss of function 
mutations in either TREM2 or TYROBP are known to cause Nasu-Hakola disease 
(Paloneva, Manninen et al. 2002). Nasu-Hakola is a disease in which patients 
develop bone cysts and also experience a peculiar form of early-onset 
neurodegeneration that ultimately leads to dementia. 
 The signaling cascade of TREM2 involves a number of secondary 
mediators to propagation the signal, in addition to TYROBP (Fig. 30). TREM2 
exists in both soluble and membrane-bound forms. When the membrane bound 
form is activated by a ligand, TREM2 associates with its adaptor protein TYROBP. 
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This then leads to phosphorylation of TYROBP by SRC kinase at its tyrosine 
residues, referred to as immunoreceptor tyrosine-based activation motifs (ITAMs), 
which then recruits Spleen Tyrosine Kinase (SYK). SYK then phosphorylates a 
number of downstream targets of the cascade, including Phosphoinositide 3-
kinase (PI3K), activation of linker for activation of T-cells family member 1 (LAT), 
Phospholipase C gamma, as well as the E3 ubiquitin-protein ligase CBL 
(Guerreiro, Wojtas et al. 2012, Colonna and Wang 2016). Activation of these 
various factors leads to changes in Calcium mobilization, activation of the RAS-
ERK pathway and actin and cytoskeletal remodeling, survival, proliferation, 
phagocytosis, and the secretion of cytokines and chemokines (Jay, von Saucken 
et al. 2017). All of the aforementioned are relevant functional aspects of microglia 
and important aspects of neuroinflammation. 
The main function of TREM2 significant to AD is the stimulation of 
macrophage and neutrophil-mediated inflammatory responses (Jay, von Saucken 
et al. 2017). This suggests that an exacerbation of TREM2 signaling may cause 
chronic, injurious neuroinflammation that leads to neurodegeneration in the 
disease context. Therefore, antagonism of the TREM2 receptor may serve to 
prevent the pathogenesis of AD. In order to pursue this topic in the current study 
antagonistic small molecules were screened and characterized for their potential 
to inhibit TREM2-TYROBP signaling in HEK293 cells. This is accomplished using 
an in-house developed split Renilla Luciferase assay (Clayton, Van Enoo et al. 
2017). Molecules were then tested for their dose-dependent inhibition to establish 
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IC50 values and inhibition of TREM2-mediated phagocytosis in BV2 murine 
microglial cells. Eventually, these data will be used to further optimize compounds 
for stronger affinity and activity in reducing TREM2 signaling. 
Chapter 6.2: Methods 
 
6.2.1: Design of the split Renilla luciferase construct 
 
 The split Renilla luciferase construct was engineered to express both 
TREM2-cLuc and TYROBP-nLuc in equimolar amounts via separation of the two 
by IRES (Varnum, Clayton et al. 2017) (Fig. 31A). Renilla luciferase is cut in half 
while TREM2 is conjugated to the C-terminal half (TREM2-cLuc) and TYROBP is 
conjugated to the N-terminal portion (TYROBP-nLuc). The cytomegalovirus 
(CMV) promoter is used for efficient expression of both portions of the construct. 
When applicable, G418 was used for antibiotic selection and made useful by the 





Figure adapted from (Colonna and Wang 2016) 





















Figure adapted from (Varnum, Clayton et al. 2017)  
Figure 31: The TREM2-TYROBP split luciferase complementation assay.  
(A) Depiction of the plasmid schematic and construct. (B) Schematic demonstrating cLuc and nLuc 






functioning luciferase enzymes 
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6.2.2: Cell culture, transfection, and luminescence measurement 
 
 HEK293 cells were used for all luciferase assays. Cells were plated at 
40,000 cells per well in 96-well tissue-culture grade opaque white clear bottom 
plates (CorningTM, #3610) for one day prior to transfection. Cells were then 
transfected with 200 ng of the TREM2-CLuc-IRES-TYROBP-NLuc plasmid 
construct using Lipofectamine 2000 (Thermo Fisher Scientific, #11668019) in Opti-
MEM (Themo Fisher Scientific, #51985091). Transfection proceeded for four hours 
before media were replaced with DMEM containing 1% P/S (Thermo Fischer 
Scientific, #15140122), and 10% fetal bovine serum (FBS, Thermo Fischer 
Scientific, #A3382001). Luciferase assays were conducted the following day. 
Luminescence was measured over 30 minutes continuously using a CentroXS3 
luminometer (Berthold Technologies, Bad Wildbad, Germany). The 
chemiluminescent solution containing Viviren (Promega, #E6491) was dispensed 
by the machine into each individual well immediately prior to the first luminescence 
read.  
6.2.3: Chemical compound library, drug screening, and calculation of IC50 
values 
 
 The BU-CMD library collection consists of over 3500 structurally complex 
small molecules that are designed and synthesized utilizing both diversity-oriented 
synthesis (DOS) strategies as well as synthetic methodologies toward complex 
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scaffolds that evolved from research projects in natural product total synthesis and 
asymmetric catalysis. The small molecule libraries were designed and constructed 
with careful consideration of physiochemical properties. In comparison to 
screening libraries that can be obtained from commercial vendors, the BU-CMD 
compounds are more stereochemically complex and have a higher proportion of 
sp3 carbon atoms (Fig. 32A). The high proportion of sp3 carbons in the collection 
gives rise to compounds that are generally “sphere-like” in shape, with a significant 
portion of “rod-like” compounds and very few compounds that are “flat”. Figure 
32B depicts the mean values of several important physiochemical property 
parameters, including lipophilicity (CLogP), molecular weight (MW), polar surface 
area (PSA) and sp3 (Fsp3) / sp2 (Fsp2) carbon contents. The average molecular 
weight of BU-CMD library members is generally higher than most commercial 
screening libraries. However, according to parameters put forth by 
GlaxoSmithKline, the low average rotatable bond count and low PSA of BU-CMD 
compounds should allow for good bioavailability independent of molecular weight. 
BU-CMD compounds thus differ significantly from commercial libraries, which 
employ hard cutoffs for molecular weights based on Lipinski’s rules (Lipinski, 
Lombardo et al. 1997).  The two anti-TREM2 antibodies used were obtained from 
R&D Systems (R&D Systems, #AF1828) and BioRad (BioRad, #MCA4772). IC50 
values were calculated using GraphPad Prism Software v8. Stimulation with either 
agonistic TREM2 antibodies or compounds took place for approximately 15 










Figure 32: Center for Molecular Discovery compound library. 
(A) Depiction of the principal moment of inertia analysis of compounds within the library (B) Table 














6.3.1: HEK293 cells transfected with the Renilla luciferase construct produce 
robust luminescence susceptible to modulation 
 
 In order to test the feasibility of using the novel Renilla luciferase assay as 
a means for drug screening, the TREM2-CLuc-TYROBP-NLuc plasmid was 
transfected into HEK293 cells and allowed to express for 24 hours. A functioning 
luciferase enzyme will hydrolyze the metabolite of exogenous Viviren, 
coelenterazine-h, producing luminescence (Fig. 33A). Following transfection, 
robust luminescence was observed over 30 minutes, peaking at around 10 minutes 
before slowly tailing off towards zero (Fig. 33B). In order to compare different 
treatment conditions and their effects on TREM2-TYROBP signaling, the average 
luminescence over 30 minutes is taken (Fig. 33C). For all studies involving the 
stimulation of cells with exogenous agents, 2% DMSO in Opti-MEM was the 
solvent unless otherwise indicated. In this manner, thousands of different 
compounds and treatment conditions can be tested for ability to modulate TREM2-



















Figure 33: Transfection of TREM2-CLuc-TYROBP-NLuc plasmid into HEK293 cells 
produces luminescence.  
(A) Illustration of catalytic processing of Viviren substrate to produce luminescence. (B) 
Representative luminescence readout over 30 minutes of cells receiving plasmid or lipofectamine 









6.3.2: The Renilla luciferase assay reliably identifies compounds with antagonistic 
and agonistic properties, as well as agonistic anti-TREM2 antibody 
 
 In order to identify compounds with the potential to pharmacologically 
modulate TREM2-TYROBP signaling, the TREM2-CLuc-TYROBP-NLuc split 
complementation assay was conducted following stimulation of HEK293 cells by 
over 3000 compounds in a comprehensive drug screening effort. Drugs that 
significantly and with sufficient amplitude (50%) increased the average 
luminescence compared to control were designated as agonist hits and 
sequestered for further testing (Fig. 34A). Those that decreased the average 
luminescence were designated as inhibitor hits and also sequestered. By the end, 
approximately 100 compounds were identified in the assay as producing significant 
and large stimulatory (agonistic) or inhibitory (antagonistic) effects on TREM2-
TYROBP signaling. These compounds were then validated via running through the 
assay an additional time to provide extra verification of their activity (Fig. 34B). By 
examining the chemical formulas and structure of validated inhibitor hits, it is 
possible to identify those compounds that possess similar chemical structure and 
likely activity in the assay (Fig. 35). Even further, a structure-activity-relationship 
(SAR) analysis can be conducted to establish a core chemical makeup that 
categorizes all compounds within a particular group that possess similar activity. 
From there, the SAR analysis infers from the effect on luminescence activity from 
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adding different functional groups what chemical changes can be made to optimize 































Figure 34: Screening of over 3000 compounds for ability to modulate TREM2-TYROBP 
signaling.  
(A) Example readout of luminescence activity of many different compounds simultaneously 
showing agonist and inhibitor hits initially identified. (B) Data demonstrating validation of inhibitor 
























































Figure 36: Table depicting the different functional groups added to a core chemical constituency 
and their average inhibition values. The color scale (grey to red) indicates the magnitude of 
inhibition for that individual chemical. 
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TREM2 has many proposed natural ligands, suggesting that biomolecules 
that specifically interact with TREM2, such as antibodies, may influence TREM2-
TYROBP signaling (Kober and Brett 2017). Therefore, in addition to many hits 
identified in the initial screen, two anti-TREM2 antibodies were tested for ability to 
modulate TREM2-TYROBP activity (Fig. 37A). One antibody appeared to have a 
potent and dose-dependent tendency to induce TREM2-TYROBP coupling and 
increase luminescence signal (Fig. 37B). At the highest concentration (20 µg/ml), 
luminescence increased continuously over 30 minutes while at 5 µg/ml, 
luminescence remained constant. Treatment with the control antibody at 20 µg/ml 
had no effect on the luminescence. Additionally, to demonstrate inhibitor hits were 
not affecting luminescence via inhibition of the luciferase itself, HEK293 cells 
transfected with a control plasmid expressing only the full-length luciferase were 
stimulated with compounds. Treatment of these cells with high micromolar 
concentrations of TREM2 inhibitor hits did not have any effect on luminescence 
(Fig. 37C). These data produce strong evidence that TREM2-TYROBP coupling 
can be influenced in vitro via stimulation of either small chemical compounds or 





















Figure 37: Antibody-induced stimulation of TREM2-TYROBP signaling.  
(A) Representative average luminescence of dose-dependent antibody stimulation. (B) 
Representative luminescence over time of agonistic TREM2 antibody compared to control antibody 





6.3.3: Top inhibitor hits exhibit dose-dependent inhibition of TREM2-TYROBP 
signaling 
 
We previously identified compounds with significant potential to inhibit or 
stimulate TREM2-TYROBP signaling. Following validation, reliable inhibitory 
concentration 50 (IC50) values need to be obtained to assess the potency of each 
compound and evaluate its current feasibility (most agonistic compounds were not 
validated). Drugs that already have relatively high IC50 values and favorable 
physiochemical properties have the potential to undergo optimization to increase 
potency. For this reason, the top six validated inhibitor hits were tested for dose-
dependent activity in the TREM2-CLuc-TYROBP-NLuc luminescence assay and 
their IC50 values were extracted (Fig. 38). The top three inhibitor hits each 
possessed a highly similar chemical structure, indicating the potential for further 
compound optimization. CMLD011616 was the most potent inhibitor hit to be 
validated and exhibit dose-dependent inhibition, achieving an IC50 of 
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6.3.4: Disease-associated TREM2 mutations decrease the potency of inhibitor 
hits 
 
Although several TREM2 mutations have been linked to neurodegenerative 
diseases such as Nasu Hakola disease and AD either as dominant or merely a risk 
factor (Jay, von Saucken et al. 2017), the nature of the mutations is not explicitly 
known. Specifically, whether these mutations effectively manifest in a loss-of-
function or a gain-of-function with regards to TREM2 signaling is not understood. 
Given that our inhibitor hits appear to significantly inhibit the coupling of TREM2-
TYROBP signaling, we tested whether or not they would possess a similar effect 
in the TREM2-CLuc-TYROBP-NLuc expressing these disease-associated TREM2 
mutations. For this, we constructed plasmids expressing the R47H mutation, 
known to be a risk factor for late-onset Alzheimer’s disease (LOAD) (Jonsson, 
Stefansson et al. 2012, Guerreiro, Lohmann et al. 2013), the T66M mutation, 
associated with FTD-like neurodegeneration (Guerreiro, Lohmann et al. 2013), 
and the S116C mutation, which causes a similar phenotype (Borroni, Ferrari et al. 
2014). As noted previously, the T66M mutation appears to dramatically increase 
the luminescence output compared to wild-type (WT) TREM2 or the other two 
disease mutations (Fig. 39A) (Varnum, Clayton et al. 2017). Our top inhibitor hit, 
CMLD011616, was used to dose-dependently inhibit TREM2-TYROBP signaling 
for each mutant TREM2 plasmid construct. For each mutation, especially R47H 
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and S116C, the derived IC50 was increased compared to that established in the 

































Figure 39: Mutations in TREM2 influence luminescence output and drug inhibition.  
(A) Time-course of simultaneous luminescence output of disease-associated TREM2 mutations. 






Chapter 6.4: Discussion 
 
 Through the development of this novel split Renilla luciferase 
complementation assay (Varnum, Clayton et al. 2017), we were able to examine 
in high-throughput fashion the potential for thousands of compounds to modulate 
TREM2 activity in a relatively simple drug screening procedure. Given that we 
began with merely 3000 compounds and identified over 100 hits in the initial screen 
is a testament to the favorable physiochemical properties of the CMLD drug library. 
Of these 100 or so hits, we validated their activity and established useful SAR to 
investigate potential optimization routes to adjust chemical formulas and 
structures.  
In addition to drug screening, we identified an agonistic TREM2 antibody 
that potently stimulated TREM2-TYROBP signaling. These findings suggest the 
TREM2-CLuc-TYROBP-NLuc complementation assay reliably provides a means 
for investigating compounds and biomolecules for the potential to influence 
TREM2-TYROBP signaling. Additionally, disease-associated mutations in TREM2 
appeared to influence the innate degree of TREM2-TYROBP signaling as well as 
their response to compound-mediated inhibition. We previously noted the 
propensity of the T66M mutation, which is thought to result in a loss-of-function of 
TREM2 considering the clinical phenotype, shifts the cellular localization of TREM2 
from membrane-bound to cytoplasmic (Varnum, Clayton et al. 2017). The T66M 
mutation drastically lowers the concentration of soluble TREM2 in the cerebral 
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spinal fluid (CSF) (Kleinberger, Yamanishi et al. 2014, Henjum, Almdahl et al. 
2016). Given these findings, it is likely the T66M mutation alters the folding of 
TREM2 to impair processing and transport to the cellular surface while 
simultaneously allowing for greater interaction with TYROBP.  
Establishing an endogenous ligand of TREM2 would shed much light on the 
potential mechanisms for how TREM2 mutation increases the risk and/or causes 
neurodegenerative disease. Generally, members of the TREM family bind lipid 
ligands (Cannon, O’Driscoll et al. 2012), and are believed to bind lipids, 
lipoproteins, and PAMPs/DAMPs (Fig. 40A). However, many of these ligands were 
tested in our TREM2-CLuc-TYROBP-NLuc split complementation assay and did 
not exhibit any activity (Fig. 40B). This is likely due to the context-dependent 
activation/inhibition of TREM2 that requires different circumstances to observe. It 
is unclear from the research of TREM2 KO and MGnD microglia modulation 
whether TREM2 inhibition or activation is the correct course of action for 















Part A adapted from (Jay, von Saucken et al. 2017) 
Figure 40: Possible ligands for TREM2 binding and activation.  
(A) Depiction of various proposed ligands of TREM2. (B) Many proposed TREM2 ligands or 
















































































































































































Chapter 7: TREM2 inhibitor hits prevent phagocytosis of S. Aureus 
particles and prevent SYK activation in BV2 murine microglia-like cells 
 
Chapter 7.1: Experimental design and Rationale: 
 
One of the important functions of TREM2 is the regulation of phagocytosis 
by microglia of CNS pathogens and insults. TREM2 is known to regulate 
phagocytosis by microglia of Aβ (Kim, Mun et al. 2017), bacteria (N'Diaye, Branda 
et al. 2009), apoptotic neurons (Hsieh, Koike et al. 2009), synapses (Filipello, 
Morini et al. 2018), and more. Impaired or hyperactive TREM2 function therefore 
could produce a strong phenotypic change in microglia that exacerbates 
neurodegenerative disease. Experiments have shown AD-related mutations in 
TREM2 expressed in BV2 microglia-like cells produce impaired phagocytic 
function (Kleinberger, Yamanishi et al. 2014). Recently it was reported that a fully 
functional TREM2 is necessary to achieve TREM2-mediated phagocytosis, while 
propagation of anti-inflammatory signaling can still be mediated through the C-
terminal fragment (Yao, Coppola et al. 2019).  
Given the large amount of reports suggesting that TREM2 is particularly 
relevant for phagocytosis in microglia and that mutations in TREM2 known to be 
associated with neurodegenerative disease impair microglial phagocytosis 
(Guerreiro, Wojtas et al. 2012, Colonna and Wang 2016), it is prudent to test 
potential inhibitors of TREM2-TYROBP signaling in a phagocytosis assay. BV2 
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murine microglia-like cell line was generated via immortalizing microglia isolated 
from the murine brain and are used frequently as a valid substitute for primary 
microglia cultures, although often producing some differences in response to 
stimuli (Henn, S et al. 2009). For this reason, we sought to assess if top compound 
inhibitor hits were able to impair TREM2-mediated phagocytosis of S. Aureus 
particles in BV2 cells. S. Aureus are bacteria recognized and phagocytosed by 
microglia (Esen and Kielian 2005). Here, we demonstrate that pretreatment of BV2 
murine microglia-like cells with top inhibitor hits of TREM2 identified in the drug 
screening assay prevented both antibody recognition of TREM2 as well as 
TREM2-mediated phagocytosis of fluorescent S. Aureus particles. 
 
Chapter 7.2: Methods 
 
7.2.1: BV2 murine-microglia cell culture, drug pretreatment 
 
BV2 cells were cultured in FBS+/PS+ DMEM in 24-well plates for (Corning, 
#3524) 24 hours prior to experimentation at approximately 100,000 cells per well 
to achieve confluency the following day. Each experimental group was run in 
triplicate. Cells were stimulated by their respective treatment condition for 15 
minutes prior to exposure to fluorescent S. Aureus particles (ThermoFisher 
Scientific, #S2851) in the media. Phagocytosis was allowed to proceed for 30 
minutes. Following incubation with S. Aureus particles, cells were digested with 
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0.25 Trypsin-EDTA (Gibco, #25200056) for 2 minutes. Digestion with trypsin both 
detaches cells from the cell plate in preparation for flow cytometry analysis as well 
as sheds particles that have stuck to cells, but have not been phagocytosed. Some 
groups were treated with SYK inhibitor instead of inhibitor hits (EMD Millipore, CAS 
622387-85-3). Trypsinization was neutralized via mixing with FBS+/PS+ DMEM. 
Next, cells were spun down via centrifugation at 500 x g for 5 minutes. Cells were 
washed with flow cytometry buffer (1% BSA in PBS) and spun down again for three 
consecutive washes. Cells were then fixed with ice cold 4% PFA in PBS for 15 
minutes while kept in the dark. To remove residual PFA, cells were washed with 
staining buffer and spun down three times again. Next, Fc receptors were blocked 
via treatment with CD16/CD32 antibody (ThermoFisher Scientific, #MFCR00-4) for 
30 minutes under gentle agitation. Following blocking, cells were stained with the 
same agonistic TREM2 antibody as mentioned in the previous chapter in flow 
cytometry buffer for approximately one hour under gentle agitation. After staining, 
cells were washed in flow cytometry buffer and spun down three consecutive 
times. Next, cells were stained with fluorescent goat anti-rat IgG secondary 
antibody (Thermo Fisher, #A-21247) for one hour under gentle agitation. After 





7.2.2: Flow cytometry analysis 
 
For flow cytometry analysis, cells were transported while covered on ice to 
the flow cytometry core. All samples were then run through the LSRII. Forward and 
side scattering allowed for exclusion of doublet cells. Dead cells were excluded via 
staining with DRAQ7 (Novus Biologicals, #NBP2-81126). Cells staining positive for 
TREM2 were distinguished from TREM2-negative cells via gating with a non-
stained control. BV2 that were not phagocytic were distinguished from phagocytic 
BV2 cells via gating with naked BV2 cells. Flow cytometry analysis was performed 
using FlowJo software (Becton Dickinson).  
 
7.2.3: SYK activation ELISA  
 
HEK293 cells were plated in 24-well plates at approximately two-hundred 
thousand cells per well in FBS+/PS+ DMEM for 24 hours prior to transfection. Cells 
were then transfected with 5 µg of plasmid expressing human TREM2, TYROBP, 
SYK, or all three together. Transfection took place in Opti-MEM using 
Lipofectamine 2000 reagent and described in Chapter 6 and proceeded for 24 
hours before media were replaced with FBS+/PS+ DMEM. Next, cells were 
stimulated with either TREM2 inhibitor, SYK inhibitor, or agonistic TREM2 antibody 
(Chapter 6) for 30 minutes. Following stimulation, cells were washed in and spun 
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down for collection. Next, they were lysed and the whole cell lysate was used in 
the ELISA. The custom SYK (Santa Cruz, #sc-166226) and phosphotyrosine 
(pTyr) (Millipore, #16-103) ELISA was conducted according to manufacturer’s 
instructions (R&D Systems, DY007). 
 
Chapter 7.3: Results 
 
BV2 murine microglia-like cells were subjected to an S. Aureus 
phagocytosis assay after being pretreated with high doses of TREM2 inhibitor hits, 
agonistic TREM2 antibody, or control antibody. Cells were also stained for TREM2 
to examine the effect of inhibitor treatment on antibody recognition. Following 
treatment with top TREM2 inhibitor hits, staining for TREM2 in BV2 cells was 
significantly reduced (Fig. 41A). CMLD011617 reduced apparent antibody 
recognition of TREM2 the most, reducing the amount of cells staining positively for 
TREM2 from 80% to approximately 30%. Treatment with control IgG resulted in no 
staining for TREM2 as expected. In addition to reducing staining for TREM2, 
treatment with 50 micromolar of TREM2 inhibitor hits significantly reduced TREM2-
mediated phagocytosis (Fig. 41B). Again, CMLD011617 had the largest effect, 
diminishing the percentage of phagocytic BV2 cells from 55% to 25%. In order to 
attenuate TREM2-mediated phagocytic function, BV2 cells were also treated with 
















Figure 41: Inhibition of TREM2-mediated phagocytose of bacterial particles.  
(A) Percentage of BV2 cells staining positively for TREM2 by group. (B) Percentage of phagocytic 





TREM2 inhibitor hits were next subjected to an assay assessing inhibition 
of TREM2-mediated activation of SYK. Activated SYK is phosphorylated in multiple 
places and can be used to measure TREM2 activation (El-Hillal, Kurosaki et al. 
1997). HEK293 cells were transfected with 5 µg of plasmid expressing either 
TREM2, TYROBP, SYK, or all three together and were stimulated with TREM2 
inhibitor hit, agonistic TREM2 antibody, or SYK inhibitor. Transfection of HEK293 
cells with 20 ug of SYK plasmid without stimulation (positive control) resulted in 
the highest concentration of phosphorylated SYK as expected (Fig. 42A). 
Additionally, cells that were triple-transfected and stimulated with agonistic TREM2 
antibody experienced a near-significant reduction in SYK phosphorylation 
following treatment with TREM2 inhibitor hit, CMLD011616. In order to assess 
whether or not TREM2 inhibitor hits were inadvertently affecting phagocytosis and 
TREM2 signaling through toxicity, HEK293 cells were subjected to a 24-hour 
cytotoxicity assay. Treatment of HEK293 cells with 50 micromolar concentrations 
of TREM2 inhibitor hits produced no increase in cell death over control (Fig. 42B). 
















Figure 42: TREM2 inhibitor hits curtail SYK activation and display no short-term toxicity.  
(A) TREM2 antibody-mediated activation of SYK is reduced by inhibitor treatment as assessed by 
ELISA. (B) Treatment of HEK293 cells with inhibitor hits after 24 hours did not produce additional 
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Chapter 7.4: Discussion 
 
 As expected, the TREM2 inhibitor hits identified in the split Renilla luciferase 
assay (Chapter 6) appeared to significantly perturb TREM2-mediated 
phagocytosis of S. Aureus particles. We expected inhibition of TREM2 to result in 
reduced phagocytosis of bacterial particles, given bacteria and other PAMPs are 
likely ligands of TREM2 (Kober and Brett 2017). Similar to the TREM2 inhibitor 
hits, inhibition of the TREM2 downstream signaling modulator, SYK, attenuated 
TREM2-mediated phagocytosis. Unexpectedly, we discovered TREM2 inhibitor 
hits also affected antibody recognition of TREM2. A reduction in antibody 
recognition, and therefore staining of TREM2 may be the result of inhibitor hits 
inducing stoichiometric change in the receptor. This could potentially result in the 
antigen being obscured. This serves as further evidence of the possibility that 
compound inhibitor hits are interacting with and influencing the activation of 
TREM2.  
 We verified the mechanism of action of inhibitor hits by looking at activation 
of prominent downstream TREM2 signaling mediator, SYK (Jay, von Saucken et 
al. 2017). Treatment with agonistic TREM2 antibody appeared to increase TREM2-
mediated activation of SYK, which was attenuated via high micromolar treatment 
with inhibitor. Lastly, high micromolar treatment with TREM2 inhibitor hits did not 
appear to increase cell death. Together, these data provide solid evidence that 
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TREM2 inhibitor hits are inhibiting TREM2 signaling as assessed at the molecular 
and functional levels. 
 
Chapter 8: Summary and Future Directions 
 
Chapter 8.1: Key findings 
 
8.1.1: Plaque compaction is mediated by microglia 
 
 We presented evidence mainly derived from the quantification of 
histological staining of several plaque markers for Aβ that showed large and highly 
significant changes to plaque morphology, size, number, and overall area across 
the medial entorhinal cortex as a result of microglia depletion (Chapter 2). Three 
different stains were utilized: Thioflavin S for dense core plaques and 4G8 along 
with 82E1 for diffuse plaques. One of the three methods produced a different result 
than the other two, demonstrating that the methodology for assessing the impact 
of microglia depletion is crucial. Understanding that the staining method utilized is 
highly relevant to our ability to observe differences is very important given the 
heterogeneous results displayed by the different studies presented in Table 2. 
Given the magnitude and significance of the results, it is appropriate to conclude 
microglia will surround and compact amyloid plaques and that plaques grow larger 
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as well as change shape significantly in the absence of microglia for prolonged 
periods. 
 
8.1.2: Propagation of pathologic tau seems to be dependent on microglia, which 
is exacerbated by amyloid burden 
 
 To ascertain the effect of microglia depletion on the propagation of 
pathologic tau, we utilized the previously-established rapid tau propagation model 
involving injection of AAV-P301L-tau into the MEC of WT and APPNL-G-F mice. We 
discovered that presence of plaques dramatically increased the propagation of p-
tau from the MEC to the GCL of the DG (almost a 10-fold increase), and that this 
effect was dramatically reduced by depletion of microglia. Microglia depletion in 
WT mice also significantly reduced the propagation rate of p-tau as well. 
Propagation rates were all derived by quantification of histological staining of p-
tau. We found similar patterns of tau propagation to the hilus and CA1 regions of 
the hippocampus, corroborating the idea that microglia contribute to p-tau 
propagation in several directions (Chapter 3). Given that propagation rates 
calculated by staining for human-specific tau generated by the AAV did not 
produce significant differences, the accumulation of pathologic p-tau is likely due 
to seeding upon endogenous mouse tau and propagation through a prion-like 
manner. These data provided compelling evidence to suggest that the propagation 
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of pathologic, disease-associated tau from relevant regions is likely exacerbated 
by the actions of microglia. We are confident of the relevance of microglia given 
the magnitude and duration of depletion in these studies.  
 
8.1.3: Accumulation of pathologic tau on amyloid plaques is dependent on 
microglia 
 
 Plaque-associated tau is a form of tau pathology that is punctate and known 
to be deposited on or very close to amyloid plaques. In this study, we demonstrate 
that the presence of NP tau is significantly increased following injection of AAV-
P301L-tau in the injected region in APPNL-G-F mice. In the absence of microglia, NP 
tau is observed to an even higher degree following injection of AAV-P301L-tau. 
The increase caused by microglia depletion is over 2-fold, suggesting microglia 
serve to alleviate the buildup of NP tau over time, although the mechanism is 
unclear. Given that depletion of microglia appears to have curtailed microglia-
mediated propagation of p-tau, it seems counterintuitive that depletion would 
exacerbate NP tau pathology. We attribute the increase in NP tau upon depletion 
to be primarily caused by increased build-up of dystrophic neurites due to larger 
and uncompacted plaques. Another possibility for the increase of NP tau is the 
loss of the protective effects of microglia against Aβ42 (Leyns, Gratuze et al. 2019). 
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Although we witnessed similar tendencies for microglia depletion to increase NP 
Tau in distal regions such as the hilus and OML, the effects were not significant.  
  
8.1.4: Plaque-associated microglia exhibit enhanced EV release and possess 
pathologic tau 
 
 Plaque-associated microglia, referred to as MGnD, exhibit a specific 
phenotype defined by unique morphological and functional characteristics (Keren-
Shaul, Spinrad et al. 2017, Krasemann, Madore et al. 2017). Given their role in 
neurodegenerative disease and our previous experiments that demonstrate EV 
release augments tau propagation (Asai, Ikezu et al. 2015), it was pertinent to 
investigate if this particular subset of microglia possessed enhanced EV secretion 
characteristics. We demonstrated through injection of our novel mE-CD9 lentivirus, 
which specifically expresses mEmerald conjugated to CD9 in microglia, that there 
were more CD9+ particles proximal to infected MGnD rather than infected 
homeostatic microglia. These data suggest that MGnD release more EVs than 
homeostatic microglia, which is difficult to demonstrate in vivo. MGnD were 
distinguished from homeostatic microglia depending on their Mac2 staining signal 
(Muraoka, Jedrychowski et al. 2021). Additionally, EVs purified from the other (also 
injected) hemispheres of the same WT and APPNL-G-F mice were subject to ELISA 
for mEmerald. mEmerald was clearly enriched in EVs compared to the brain 
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homogenate. mEmerald signal was increased in the APPNL-G-F EVs compared to 
WT EVs, although it was not statistically significant. This suggests microglia are 
releasing EVs more in the APPNL-G-F brain compared to the WT brain, likely due to 
their phenotypic conversion to MGnD. Additionally, we isolated both MGnD and 
homeostatic microglia populations from APPNL-G-F mouse brains and conducted 
qPCR for prominent tetraspanins. We found an upregulation of both CD9 and 
CD63, providing strong evidence that MGnD are overproducing the proteins 
necessary for EV secretion compared to non-MGnD microglia.  
 Next we investigated whether the greater quantities of EVs released from 
MGnDs also contained pathologic p-tau within them. In order to investigate this 
possibility, we conducted sequential injection of mE-CD9 lentivirus and AAV-
P301L-tau into the MEC. This allowed for the direct visualization of the 
incorporation of mE-CD9+ and pathologic p-tau into microglia-derived EVs. High 
resolution confocal images revealed pathologic p-tau encapsulated within mE-
CD9+ voxels surrounding microglia in the p-tau+ region of the MEC. Confocal 
images were supplemented with immuno-EM images showing p-tau within mE-
CD9+ EVs. These data were strong evidence that microglia can release pathologic 
tau within their EVs. 
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8.1.5: TREM2 inhibitor hits were identified in an in-house developed split Renilla 
luciferase assay 
 
 Using the split Renilla luciferase complementation assay developed in our 
lab (Varnum, Clayton et al. 2017), we were able to identify compounds that 
appeared to possess significant inhibition of TREM2-TYROBP signaling. Our 
results were validated through multiple follow-up tests and through the 
characterization of dose-dependent curves and IC50 values. In addition, we used 
an agonistic TREM2 antibody in order to induce TREM2 signaling as a positive 
control in the assay. Our assay demonstrated robust and reproducible inhibition 
and stimulation of TREM2 signaling. The data were further corroborated by the 
analysis of chemical formulas and structures (SARs) that revealed the high 
structural similarity between inhibitor hits. These findings strongly suggest our 
Renilla luciferase assay was able to successfully screen thousands of compounds 
and identify those which possessed activity in inhibiting TREM2 signaling.  
 
8.1.6: Compound hits appear to inhibit TREM2-mediated signaling and function 
 
 Compound hits identified in the luciferase assay drug screen were tested in 
three assays to assess their ability to inhibit TREM2 signaling. In the phagocytosis 
assay, treatment of cells with high micromolar concentrations of TREM2 inhibitor 
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hits resulted in dramatically reduced phagocytosis in an immortalized microglia cell 
line. TREM2-mediated phagocytosis of bacterial particles was corroborated by the 
administration of an agonistic TREM2 antibody leading to enhanced phagocytosis. 
At the molecular level, we demonstrated through measuring the concentrations of 
phosphorylated SYK following TREM2 activation, that treatment with compounds 
were inhibiting TREM2 signaling. In the last assay, we demonstrated there was no 
increase in the short-term death of cells following treatment with high micromolar 
concentrations of TREM2 inhibitor, suggesting low levels of toxicity and lowering 
the possibility of our findings being off-target effects. Given these data, it is likely 
our compounds were inhibiting TREM2 signaling directly and not through aberrant 
off-target effects. 
 
Chapter 8.2: Conclusions and Future Directions 
 
The role of microglia and their contribution to neurodegenerative disease is 
a burgeoning field that has only begun to be investigated. We discussed previously 
the myriad genes associated with or expressed primarily in microglia that are risk 
factors for several neurodegenerative diseases (Hickman, Izzy et al. 2018). 
Microglia react fiercely to the pathology of AD and migrate to regions of insult. They 
engulf and dispose of harmful protein aggregates while releasing neurotrophic 
factors and other molecules to stimulate repair to damaged areas. Given the 
incredible attributes of microglia, we can safely surmise that microglia have a 
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unique potential to be utilized for therapeutics purposes not just for 
neurodegeneration, but all CNS disorders. However, chronic activation of microglia 
can lead to harmful neuroinflammation and permanent disruption of CNS 
homeostasis, which exacerbates neurodegenerative disease. It is therefore 
prudent to develop a meticulous characterization of how and when to modulate 














Over the course of these experiments, we made many discoveries that 
illuminate the peculiarity of microglia and their roles in influencing different aspects 
of AD pathology. On the one hand, microglia clearly have an important duty to 
compact and contain harmful neuritic plaques given that absence of microglia 
results in greater number and accumulation of plaques. The data on plaque 
compaction we presented could be supplemented with additional biochemistry 
techniques to determine the degree to which microglia can influence the makeup 
of individual Aβ units such as fibrils, oligomers, or individual peptides within 
plaques. Additionally, a form of a pathology gaining recent attention, NP-tau, was 
also found to be exacerbated by the depletion of microglia. Plaque-associated 
accumulation of pathologic tau is observed in both mice and humans (He, Guo et 
al. 2017), but is ill-defined phenomenon. It can be described as extracellular 
deposits of p-tau aggregates, or within dystrophic neurites (Leyns, Gratuze et al. 
2019). However, it is clear that NP tau can influence the sequestration and 
manifestation of tau pathology in the APPNL-G-F mouse model. On the other hand, 
propagation of pathologic p-tau from the MEC to the GCL of the DG was 
significantly curtailed by depletion of microglia. The reason for why microglia alter 
the manifestation and propagation of different forms of tau pathology is yet to be 
fully understood. These data provide clues as to the multiple unique roles that 
microglia possess, but complicate therapeutic strategy.  
An increased EV release profile in disease associated microglia can have 
many implications for our understanding of MGnD and their ultimate role in 
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neurodegenerative disease and must be investigated further. Particularly, these 
microglia-derived EVs contained pathologic p-tau and may be contributing to the 
propagation of pathologic tau species. If these EVs are then integrated into distal 
neurons to seed aggregation, it could potentially drive neuronal death in the 
hippocampus and other areas, translating to memory loss and cognitive decline. 
Future studies investigating propagation of tau through EV release should 
incorporate assessments of neuronal death in histopathology studies and 
behavioral studies in mice to assess cognitive decline. If MGnD microglia 
hypersecrete EVs, it could certainly serve an alternative purpose that is beneficial 
to neurons and other glia, and thus perturbing this function of MGnD microglia 
could worsen outcomes as opposed to alleviating them. All of this is yet to be 
determined. 
We and others demonstrated the ability of microglia to be pharmacologically 
depleted without ostensible side effects very efficiently and for prolonged periods 
of time, which is a valuable tool to bettering our understanding. There is also the 
potential for repopulation of microglia from remaining microglia themselves or from 
injection into the CNS of cultured microglia-like cells to study microglia from a more 
nuanced approach (Abud, Ramirez et al. 2017). Other techniques to genetically 
modify microglia through lentivirus transduction also provide great opportunity to 
study microglia in their native setting. We also demonstrated the potential for 
pharmacologically-influencing the disease-relevant activities of microglia through 
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drug or antibody administration in vitro, further suggesting pharmacological 
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